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ABSTRACT 
Current swine influenza vaccines fail to protect against the broad range of strains 
circulating within the United States.  To induce effective broad cross-protection against 
influenza, strong humoral and cell-mediated immune responses are needed.  However, 
animals are often vaccinated at a young age when they exhibit a host of dysregulated or 
insufficient immune responses including biased T cell polarization and immature 
inflammatory responses.  Porcine neonates have diminished expression of IL-18 in their 
respiratory tract, a major site of infection in young animals.  Initially named interferon- 
inducing factor (IGIF), IL-18 is most widely known for its potent ability to up-regulate 
expression of interferon- (IFN-, resulting in a phenotypic TH1 driven T cell polarization.  
For many infections, such as influenza, deficiencies in IL-18 expression have been shown to 
result in deleterious effects on the development of protective immune responses.  Insufficient 
expression of IL-18 during neonatal development in swine may result in a reduced expansion 
of a TH1 immune response and may result in improper immunological polarization in 
response to vaccination.  Based on findings by Kim et al. (2001), two amino acid conversions 
were introduced (E41A & K88A) to porcine IL-18 by PCR primer site directed mutagenesis.  
Synonymous mutations to human IL-18 (huIL-18) by Kim et al. (2001, 2002) resulted in 4-
fold increases in biological activity and extended half-life.  Replication-defective 
adenoviruses expressing either the wild type porcine IL-18 or the mutated form was 
generated.  Additionally, to create a succinct swine influenza modified live virus (MLV) 
vaccine expression rIL-18 protein, the mutated form of IL-18 (mutIL-18) was inserted into 
the truncated region of the NS1126 gene of an attenuated H3N2 modified live swine 
xii 
 
influenza virus.  The properties of biological expression and biological activity of both wild 
type IL-18 and mutated IL-18 were assessed in vitro and in vivo.  Replication-defective 
adenovirus expression vectors were confirmed to express high levels (>10ng/mL) of wild 
type and mutated forms of IL-18.  The rIL-18 expressing constructs (MLV+mutIL-18, 
MLV+Ad5wtIL-18, and MLV+Ad5mutIL-18) were administered as single dose influenza 
vaccines.  The immunomodulatory effects of wild type and mutated forms of IL-18 were 
evaluated for their efficacy to enhance the immune protection afforded by the MLV vaccine 
alone in response to heterosubtypic influenza challenge (H1N1).  The MLV+Ad5mutIL-18 
vaccination group resulted in significantly higher antibody titers post challenge compared to 
the MLV alone.  Additionally, both groups receiving either mutIL-18 construct 
(MLV+mutIL-18, MLV+Ad5mutIL-18) exhibited significantly lower viral shedding post 
challenge, lower viral replication in the lungs, and reduced microscopic lung lesion scores at 
time of necropsy.  Flow cytometric analysis of circulating lymphocyte populations revealed 
significant differences in cell populations between IL-18/non-IL-18 groups and adenovirus 
and non-adenovirus groups.  CD4+CD8+ double positive (DP) and  T cells were the main 
cell populations activated upon influenza vaccination and heterosubtypic challenge.  Results 
indicate that, along with rIL-18 administration, the type of expression vector (adenovirus or 
influenza) plays a significant role in determining cytokine expression and responding T cell 
populations 
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CHAPTER 1 INTRODUCTION 
1. General Introduction 
Young animals are known to exhibit impaired or insufficient immune functions such 
as decreased production of inflammatory mediators and an impaired ability to formulate a 
phenotypic TH1 based T cell response (Sarzotti et al., 1996; Siegrist, 2001; Suen et al., 1998).   
The immunologically altered state of young animals makes them particularly vulnerable to 
developing insufficient or unprotective immune responses following infection or vaccination.  
Specifically, pigs have been shown to exhibit a significant reduction in interleukin (IL)-18 
expression in the mucosal epithelium for months after birth (Muneta et al., 2002).  In that 
study, the mucosal epithelial cells were additionally unable to up-regulate interferon- (IFN-
) expression upon concanavalin A (Con A) stimulation.  However, treatment of the same 
cells by exogenous IL-18 resulted in IFN- production.  Therefore, the administration of 
exogenous cytokines may help restore correct immune function and, in conjunction with 
vaccines, may help generate enhanced immune responses.   
Influenza is an acute respiratory illness often accompanied with secondary bacterial 
infections in severe cases (Brundage, 2006).  Swine influenza is a common component 
contributing to the porcine respiratory disease complex (PRDC) (Baskerville, 1981) and was 
ranked the second leading cause of productivity losses by swine producers (Holtkamp et al., 
2007).  To protect against a broad range of influenza viruses, next generation influenza 
vaccines will need to elicit a strong adaptive immune responses comprising both cell 
mediated and humoral immune elements.  While pre-existing antibody is the only known 
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mechanism to achieve sterilizing immunity to influenza (Gerhard, 2001), mutations (drift) 
and reassortment events (shift) result in swiftly changing antibody recognized epitopes.  
Inversely, T helper and cytotoxic T cells typically recognize more static internal influenza 
proteins possessing conserved epitopes (Doherty et al., 1997; Doherty et al., 2006; Flynn et 
al., 1999; Thomas et al., 2006).  Recovery from established influenza infection is primarily 
mediated by cellular immune responses (Graham and Braciale, 1997; Topham et al., 1996).  
Studies with IL-18 deficient (IL-18 
-/-
) transgenic mice have demonstrated the need for 
adequate IL-18 expression for normal recovery from influenza infection.  IL-18 
-/-
 transgenic 
mice infected with influenza A virus resulted in (a) a higher rate of viral replication, (b) 
significantly elevated viral titers, (c) significantly lower IFN-γ production, and (d) lower 
activity levels of NK cell-mediated cytolysis (Billaut-Mulot et al., 2000; Denton et al., 2007; 
Dinarello, 1999; Foss et al., 2001; Liu et al., 2004; Takeda et al., 1998).  Further research 
showed IL-18 is required for optimal production of cytokines IFN-γ, TNFα, and IL-2 from 
CD8+ T cells during the course of influenza infection (Denton et al., 2007).  Consequently, 
administration of IL-18 in conjunction with influenza vaccination may result in a more robust 
CMI response conveying stronger protective immunity. 
Cytokine administration for therapeutic immunomodulation has been able to restore 
correct immune function (Pertmer et al., 2001; Ridge et al., 1996; Siegrist, 2001) or enhance 
protective immunity (Zuckermann et al., 1998).  However, a short half-life in vivo is a 
particular problem concerning the use of recombinant cytokine protein for therapeutic 
purposes.  To evaluate the immunomodulatory effects of recombinant porcine IL-18 in 
conjunction with vaccine administration, IL-18 viral expression vectors were generated from 
a replication-defective adenovirus and a modified live swine influenza virus.  Furthermore, to 
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generate an enhanced immunomodulatory agent, two amino acid conversions were 
introduced to wild type porcine IL-18 (E41A & K88A).  Mutations were completed by PCR 
site directed mutagenesis, with which two charged amino acids critical for binding to the 
inhibitory IL-18 binding protein (IL-18BP) were converted to alanine (Figure 1.1).  Previous 
research introducing synonymous mutations to human IL-18 (huIL-18) resulted in enhanced 
biological activity and extended half-life (Kim et al., 2001).   
Properties of biological expression and biological activity of recombinant IL-18 (rIL-
18) were evaluated both in vitro and in vivo.  To assess the immunomodulatory effect of rIL-
18 on the immune response to influenza vaccination, both wtIL-18 and mutIL-18 expression 
vectors were administered in conjunction with a previously described modified live swine 
influenza virus vaccine (Tx98NS1126) (Richt et al., 2006; Solorzano et al., 2005).  
Vaccination groups were evaluated in response to heterosubtypic challenge [H1N1 IA04].  
Flow cytometric analysis post vaccination, pre challenge, and post challenge identified 
CD4+, CD8+, and  T cell populations expressing CD25, IFN-, and IL-10 [as activation, 
TH1, and TH2 markers respectively].  Results indicate the co-administration of rIL-18 with 
the modified live influenza virus vaccine conveys a stronger level of protection against 
heterosubtypic challenge compared to the modified live influenza vaccine alone.   
 
2. Thesis Organization 
This thesis is organized in the alternative format.  In the first chapter, after the general 
introduction, a review of pertinent literature is presented.  Chapters two and three are the 
authors own work formatted for publication in Veterinary Immunology and 
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Immunopathology.  General conclusions are discussed in Chapter 4.  Citations are displayed 
at the end of each chapter in separate bibliographies.   
The main author contributed to the development and planning of research, conducted 
experiments, evaluated data, and authored the primary manuscript.  Dr. Wen-jun Ma 
generated the mutated IL-18 cDNA construct and the influenza MLV containing the mutated 
IL-18 cDNA construct.  Dr. Jürgen Richt assisted in the generation of the mutated IL-18 
cDNA construct and the generation of the influenza MLV containing the mutated IL-18 
cDNA construct.  Drs. Amy Vincent and Kelly Lager aided in the planning and execution of 
experiments.  Dr. James Roth contributed to the planning and execution of experiments and 
to the writing of the manuscript.  Dr. Ratree Platt conducted the flow cytometry CMI study 
and evaluated the flow cytometry data.  Dr. Michael Murtaugh provided the wild type 
porcine IL-18 cDNA plasmid.  Dr. Marcus Kehrli conceived of the experimental concept, 
contributed to the planning and execution of experiments, aided in the evaluation of data, and 
to writing of the manuscript.   
 
3. Literature Review 
3.1 Interleukin-18 
Properties of IL-18 
IL–18 was first identified as a soluble protein from the sera of mice pretreated with 
Propionibacterium acnes which markedly increased interferon- (IFN-protein production 
in resting splenic nonadherent cells upon administration (Nakamura et al., 1993).  Since the 
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initial discovery, IL-18 has been cloned and characterized from many species including mice 
(Okamura et al., 1995), humans (Ushio et al., 1996), and swine (Muneta et al., 2000).  
Currently, the full genetic sequence of IL-18 has been identified from at least 14 species 
(NIH, 2009).  IL-18 is secreted by a variety of cells including macrophages, dendritic cells, T 
cells, neutrophils, Kupffer cells, and epithelial cells (Akira, 2000; Fortin et al., 2009; 
Nakanishi et al., 2001; Stoll et al., 1998).  IL-18 expression can be activated by TLR 
signaling (Akira et al., 2001), induced by IFN- via ICSBP (interferon consensus sequence-
binding protein) and AP-1 (activator protein-1) pathways (Kim et al., 2000), by 
inflammasome activation (Stasakova et al., 2005), or by autocrine signaling through the NF-
B (nuclear factor kappa-light-chain-enhancer of activated B cells) pathway (Fortin et al., 
2009).  In the presence of IL-12, IL-18 induces strong TH1 type immune responses (Denton 
et al., 2007; Liu et al., 2004; Nakamura et al., 1993; Takeda et al., 1998), primarily through 
the induction of IFN- expression by T cells and natural killer cells (Dinarello, 1999; 
Yoshimoto et al., 1997).  As a potent inducer of IFN-expression, IL-18 is characterized as a 
member of the TH1-inducing cytokine family along with IFN-, IL-2, IL-12, and IL-15 
(Dinarello, 1999).   
IL-18 is expressed as a biologically inactive precursor protein.  The 192 amino acid 
pro protein (24kDa) lacking an exportation signal sequence is stored in intracellular vesicles 
until activation.  Upon stimulation of the inflammasome complex, IL-1 cleaving enzyme 
(caspase-1 or ICE) is cleaved into the active form.  Mature caspace-1 is than able to cleave 
pro-IL-18 at the Asp-X site of amino acid position 35.  Cleavage at position 35 results in a 
biologically active 18kD mature IL-18 protein (Ghayur et al., 1997; Gu et al., 1997; NIH, 
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2009).  Cleavage by caspase-3 at Asp71-Ser72 or Asp76-Asn77 on either pro or active IL-18 
protein results in a biologically inactive protein (Akita et al., 1997).  IL-18 neutrophil 
stimulation activates cleavage of both pro and active IL-18 forms into a variety of products, 
possibly by serine proteases elastase and cathepsin G (Gracie et al., 2003), but the biological 
significance of those products is yet unknown.   
IL-18 activity results from the signaling cascades activated from binding to the IL-18 
receptor complex (IL-18R).  IL-18R is 60-100kD in size and shares 35% sequence identity 
with IL-1RI (Dinarello, 1999; Kojima et al., 1998).  IL-18R is comprised of an IL-18R 
binding chain (IL18R1 or IL1Rrp) and a IL18R signaling chain (formerly IL18RAP or 
IL1AcPL) (Dinarello, 1999).  Affinity of IL-18 for the IL-18Rchain is reported at a (Kd) of 
25nM, which is a relatively low for the known picomolar activity range of IL-18 (Thomassen 
et al., 1998).  However, after IL-18 binds to IL-18R, the IL18R signal chain is quickly 
recruited to form a high affinity heterodimeric complex, able to activate downstream 
intracellular signaling cascades (Dinarello, 1999).  Amino acid residues Lys79, Lys84, and 
Asp98 on huIL-18 were found to be biologically important for the induction of IFN- even 
though these residues are not involved in IL-18R receptor binding (Kato et al., 2003).  
Further assessment identified the residues as important amino acids for the binding of IL-
18R to the IL-18/IL-18R complex, though IL-18could not bind to IL-18 or the IL-
18Ralone (Kato et al., 2003).  These results indicate the IL-18R and IL-18R chains bind 
to different locations on the IL-18 protein, but interact to cause a change in ligand affinity as 
the heteromeric complex is formed.   
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Once bound to IL-18, the IL-18R complex signals through the IRAK (IL-1R-
activating Kinase) (Dinarello, 1999; Kojima et al., 1998), TRAF-6 (TNFR-associated factor-
6), NF-B (Kojima et al., 1998), MyD88 (Adachi et al., 1998), and p38 mitogen activated 
protein kinase (MAPK) pathways (Fortin et al., 2009; Gracie et al., 2003).  Most notably, IL-
18 signaling up-regulates the expression of IFN- but also results in activation of a variety of 
other antiviral, antimicrobial, and antifungal associated immune functions (Akira, 2000; Biet 
et al., 2002; Fortin et al., 2009; Foss et al., 2001; Liu et al., 2004; Pirhonen et al., 1999; 
Zhang et al., 1997).  Specifically, IL-18 activates T cells to synthesize IFN-, IL-2, 
granulocyte-macrophage colony-stimulating factor (GM-CSF), tumor necrosis factor– 
(TNF ) , IL-1 and IL-8 (Dinarello, 1999; Kohno et al., 1997; Puren et al., 1998; Ushio 
et al., 1996).  IL-18 also potentiates the expression of Fas ligand (Ohtsuki et al., 1997) 
resulting in enhanced NK and CTL cell cytotoxicity and apoptotic killing of infected cells 
(Akira, 2000). 
 
IL18 and IL12 act synergistically to induce TH1 immune responses 
Both IL-12 and IL-18 are characterized as prototypical TH1 cytokines for their potent 
abilities to up-regulate IFN- protein expression.  In many models, research has shown IL-12 
or IL-18 cytokines produce negligible quantities of IFN- protein individually, but act 
synergistically to induce high levels of IFN- production when administered together 
(Denton et al., 2007; Dinarello, 1999; Kohno et al., 1997; Liu et al., 2004; Robinson et al., 
1997; Takeda et al., 1998; Yoshimoto et al., 1998).  However, IL-12/IL-18 co-induction may 
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not always be needed to elicit high quantities of IFN-.  Kehrli (2003) was able to induce 
high IFN- concentrations utilizing IL-18 treatments alone in a bovine model (Kehrli, 2003).   
IL-12 acts not only to activate the IFN- pathway via STAT3/STAT4 signaling but 
also acts to up-regulate IL-18R on primed T cells (Yoshimoto et al., 1998).  As the inhibitory 
IL-18BP competes with IL-18R for IL-18 binding, up-regulating IL-18R on primed T cells 
results in an increased sensitivity to IL-18 and thus stronger induction of IFN- expression.  
On anti-CD40 primed B-cells, IL-18 in the presence of IL-12 induces production of IFN- 
and inhibits IgE and IgG1 subclass production (Yoshimoto et al., 1997).  IL-18/IL-12 co-
administration has also been shown to induce subclass switching to the complement 
activating IgG2 isotype (Moran et al., 1999).   
IL-18 and IL-12 act to up-regulate IFN- expression by different signaling pathways.  
IL-18 activates the IFN- promoter at the AP-1 site, whereas IL-12 acts at a STAT4 initiation 
site (Dinarello, 1999).  AP-1 activation via IL-18 signaling is alone sufficient for IFN- 
transcription, while STAT4 signaling needs a secondary signal such as anti-CD3 or anti-
CD28 (Dinarello, 1999).  When IL-18 and IL-12 are present, both activation sites are 
stimulated, a mechanism by which IL-18/IL-12 co-induction acts synergistically to enhance 
IFN- expression.   
 
Interleukin-18 binding protein 
IL-18BP was first isolated as a protein product binding to an IL-18-agarose column 
from the urine of healthy subjects (Novick et al., 1999).  One of the major regulatory 
elements of IL-18 signaling, IL-18BP competes with IL-18R to bind IL-18 protein.  IL-18BP 
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abolishes biological activity of IL-18 upon binding (Novick et al., 1999).  In COS7 cells, rIL-
18BP treatment abolished IL-18 inducted expression of IFN- and IL-8 (Novick et al., 1999).   
Figure 1.1  Chemical structure comparison of mutated IL-18 amino acid conversions 
 
Fig. 1.1.  PCR primer site directed mutagenesis was utilized to introduce two amino acid conversions, E41A & K88A, into 
wild type porcine IL-18.  Mutations are synonymous to mutations introduced to human IL-18 (E42A & K89A) by Kim et al. 
(2001). 
 
IL-18BP is not a variant of the IL-18R and shares no significant homology with the 
IL-18R, making IL-18BP unique among soluble cytokine receptors (Novick et al., 1999).  
Most soluble cytokine receptors are variants of the cell surface receptor lacking the 
transmembrane domain.  Conversely, IL-18BP shares a unique identity to a family of 
secreted proteins belonging to the immunoglobulin superfamily (Novick et al., 1999).  
Because of the differences between IL-18R and IL-18BP, mutations introduce to the IL-
18/IL-18BP interface were able to abolish IL-18BP binding and enhance biological activity 
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of huIL-18 (Kim et al., 2002; Kim et al., 2001).  Research showed site-specific mutations 
altering charged residues E42A or K89A (Figure 1.1) of recombinant human IL-18 (rhuIL-
18) resulted in a 2-fold increase in biological activity.  A E42A / K89A double mutant 
additionally exhibited a 4-fold increase in biological activity and was rendered fully resistant 
to IL-18BP neutralization (Kim et al., 2001). 
 
3.2 Unique attributes of the porcine immune system 
The porcine immune system is unique compared to most other species.  Porcine lymph 
nodes exhibit an inverted lymph node structure compared to most other animals, as the 
medulla is external to the cortex (Binns, 1982).  The recirculation of lymphocytes directly 
entering into the blood from the lymph node capillaries instead of efferent lymph node 
tubules is also unique (Carr et al., 1994; Nayeem et al., 1997; Pescovitz et al., 1994; Yang 
and Parkhouse, 1996).  Additionally, the porcine immune system possesses unusually high 
γ/δ and CD4+CD8+ double-positive (DP) T cell populations (Carr et al., 1994; Nayeem et al., 
1997; Pescovitz et al., 1994; Yang and Parkhouse, 1996).  While the use of swine as a 
research model has greatly increased in recent years due to the interest in swine-to-human 
xenograft transplantation, their similarities to human physiology, and the elevated 
populations of γ/δ and CD4+CD8+ DP T cells; characterization of the porcine immune 
system, is lacking in comparison to human and murine models.   
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T-cell populations 
T cells can be categorized partially based upon  and  T cell receptors (TCR).  
-TCR+ T cells can be loosely divided into cytotoxic verses T helper categories, and T-
helper cells further into TH1, TH2, and TH17.  NK T and regulatory T cells have also been 
identified but are poorly understood.  γ/δ T cells are a T cell subclass for which mechanisms 
and functions are still incompletely understood.  γ/δ T cells are believed to play a role in a 
variety of immune functions including T cell regulation, immunosurveillance, T cell 
tolerance, antigen-dependent and antigen-independent detection of pathogens, T helper like 
function, cytotoxic effects, APC like activation of B cells, antibody class switching, and are 
largely associated with the mucosal immune system (Fujihashi et al., 1996; Hayday et al., 
2000; Horner et al., 1995; King et al., 1999; Rivas et al., 1989; Takamatsu et al., 2006; Wen 
et al., 1998). 
Neonatal pigs have at least four  T cell populations in [CD4+CD8-, CD4+CD8lo, 
CD4
-
CD8
lo
, CD4
-
CD8
hi
] (Yang and Parkhouse, 1996).  Characteristically, single positive 
(SP) T cells CD4+ (CD4
+
CD8
-
) and CD8+ (CD4
-
CD8
hi
) are largely categorized based upon 
their expression of cytokines and cellular functions.   
γ/δ T cells were formerly classified as ‘null’ cells due to their lack of conventional T 
or B cell markers.  Subsets are not well defined but have been suggested to include CD2
-
CD4
-
CD8
-
, CD2
+
CD4
-
CD8
lo
, and CD2
+
CD4
-
CD8
-
 (Takamatsu et al., 2006; Yang and 
Parkhouse, 1996).  At least 12 CR+ thymocyte subclasses have been identified in 
prenatal and postnatal swine based on cell surface markers (Sinkora et al., 2005), some 
describing different developmental stages of the CR+ thymocyte.   
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γ/δ T cells are found in high numbers in peripheral blood and lymphoid tissues of 
sheep, cattle, and pigs (Nayeem et al., 1997; Takamatsu et al., 2006; Thome et al., 1993; 
Yang and Parkhouse, 1996) and preferentially home to extra-lymphoid epithelial-associated 
tissues (Nayeem et al., 1997).  They are known to be able to recognize target antigens in an 
MHC independent manner (Takamatsu et al., 2006), which may allow them to respond in a 
shorter period following infection.  γ/δ T cells are involved in the innate and acquired 
immune functions at the mucosal surface.  A considerable deficiency in neutrophil 
infiltration to the lung and marked reduction in IgA production is reported in γ/δ-deficient 
transgenic mice (Fujihashi et al., 1996; King et al., 1999).  Moreover, subsets of γ/δ T cell 
have been reported to conform to the TH1/ TH2 paradigm in both cytokine production and 
function (Wen et al., 1998).  Additionally, γ/δ T cells possess cytotoxic effects [CD3+CD4-
CD8
-
] in an antigen specific manner (Rivas et al., 1989), and aid in B cell stimulation and 
antibody isotype switching (Horner et al., 1995).   
γ/δ T cells are the predominant TCR+ cell class in young pigs, found in high numbers 
both in the peripheral blood and in lymphoid tissues (Holtmeier et al., 2004; Yang and 
Parkhouse, 1996).  The elevated prevalence of CD4
+
CD8
+
 T cells in the resting peripheral T 
cell population is unique to ungulates (Pescovitz et al., 1994).  γ/δ T cells are most abundant 
at neonatal age in swine and reduce as the pig reaches adulthood (Nayeem et al., 1997).  
Unlike γ/δ T cells, porcine CD4+CD8+ DP T cell numbers increase with age and have been 
identified as a major class of memory T cells within the pig (Pescovitz et al., 1994).   
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Deficiencies of the neonatal immune system 
Neonatal animals are particularly vulnerable to pathogens due to their 
immunologically naïve state.  The neonatal immune system is known to display a host of 
dysregulated or insufficient immune functions including inflammatory, innate, and Th1/Th2 
T cell polarization responses (Forsthuber et al., 1996; Pertmer et al., 2001; Ridge et al., 1996; 
Sarzotti et al., 1996).  Neonates exhibit an impaired ability to formulate a phenotypic TH1 
immune response, but the exact mechanism(s) is yet unknown (Forsthuber et al., 1996; 
Pertmer et al., 2001; Ridge et al., 1996; Sarzotti et al., 1996; Siegrist, 2001; Siegrist et al., 
1998; Suen et al., 1998).  IL-18 expression in porcine neonates is markedly diminished at the 
mucosal surfaces in young piglets (Muneta et al., 2002).  As IL-12 in the absence of IL-18 is 
a poor inducer of TH1 T cell development, insufficient constitutive expression of IL-18 
during the neonatal development period may contribute to the reduced induction of a TH1 
based immune response in swine neonates.  Due to the deficiencies of the neonatal immune 
system, infections and vaccinations that occur within the first stages of life may result in 
insufficient or unprotective acquired immune responses.   
 
3.4 Overview of swine influenza  
General background of swine influenza 
The influenza type A virus is an enveloped negative stranded RNA virus composed of 
eight genomic segments.  Influenza belongs to the Orthomyxoviridae viral family and is 80-
120nm in size (Heinen, 2003).  Classification of influenza A viruses are based upon two 
antigenically important glycoproteins, hemagglutinin and neuraminidase.  Currently there 
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have been 16 hemagglutinin and 9 neuraminidase subtypes identified (Fouchier et al., 2005; 
Olsen et al., 2006a; Skehel, 2009; Webster et al., 1992).  In humans, influenza infection is 
typically characterized as an upper respiratory infection resulting in high fever, myalgia, 
headache, non-productive cough, sore throat, and rhinitis (WHO, 2003), with similar 
symptoms in swine.  Influenza virus is transmitted by large droplet aerosols like coughing or 
sneezing or by direct transmission via physical contact with a contaminated surface or 
infected individual.  In the United States, the WHO estimates direct and indirect losses due to 
seasonal influenza infection in humans to be between $71-$167 billion annually (WHO, 
2003).  Worldwide, it is estimated that 3 to 5 million severe influenza infections will develop 
annually resulting in 250,000 to 500,000 deaths (WHO, 2003).  Infected individuals will 
typically be contagious from one or more days prior to onset of symptoms until 5-7 days after 
onset (Prevention, 2007).  Four pandemics have occurred within the past century dating back 
to the 1918 H1N1 Spanish flu pandemic, which is believed to have caused up to 50 million 
deaths (de Wit and Fouchier, 2008).  Pandemics resulted from introductions of the H2N2 
subtype in the 1957 Asian flu pandemic and H3N2 subtype in the 1968 ‘Hong Kong’ flu 
pandemic (de Wit and Fouchier, 2008; Keen, 1995) and a novel H1N1 swine like influenza 
virus in 2009 (WHO, 2009).   
Influenza epidemics and pandemics in humans have been noted for centuries (Anon., 
1890) but had not been correctly attributed to any specific etiology until first isolated from 
samples of infected swine in 1931 (Shope, 1931b).  Swine influenza was initially 
documented clinically during the 1918 pandemic and has been circulating in the swine 
population since that time (Koen, 1919; Shope, 1931a).   
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In the swine industry, seasonal swine influenza infection was ranked the second 
leading cause of productivity losses by swine producers (Holtkamp et al., 2007).  Close 
relationships exist between swine and human influenza viruses.  Introduction of human 
influenza viruses into the swine population dates back to at least the 1918 pandemic where it 
is believed the human H1N1 virus crossed over into swine (Reid et al., 1999; Shope, 1931a).  
At least three other human introductions to swine populations have occurred since that time 
(Richt et al., 2003).  Due to the uncommon physiology of swine respiratory epithelia, pigs are 
considered a potential mixing vessel capable of genetic reassortment (genetic shift) between 
multiple influenza lineages.  Porcine upper airway epithelia have been shown to express both 
avian ( 2,3) and human (2,6) receptor linkages, enabling swine to be infected by influenza 
viruses from avian, human, and swine lineages (Ito et al., 1998; Ito and Kawaoka, 2000; 
Landolt et al., 2006; Massin et al., 2001; Neumann and Kawaoka, 2006; Stern and Tippett, 
1963; Suzuki et al., 2000).  Both the 1957 and 1968 human pandemic viruses contained 
genomic segments from an avian lineage (Kawaoka et al., 1989).  However, fully avian 
parental viruses were never isolated from the human population during either pandemic, 
indicating reassortment may have occurred in an intermediate host (Webster, 1972; Zhou et 
al., 1999).  In 1998 many novel influenza A viruses of a new subtype, H3N2, were detected 
as a quickly spreading infection in the United States swine herds.  The novel viruses were 
initially characterized as double reassortant and triple reassortant genotypes composed from 
swine, human, and avian influenza viruses (Webby et al., 2000).  Triple reassortant H3N2 
viruses contained the hemagglutinin (HA), neuraminidase (NA), and polymerase basic 1 
(PB1) genomic segments from human lineage; the nucleoprotein (NP), matrix (M), and non-
structural (NS) segments from the classical swine influenza viruses, and polymerase basic 2 
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(PB2) and polymerase acidic (PA) segments from avian viruses (Webby et al., 2000; Zhou et 
al., 1999).  Prior to the identification of the double and triple reassortant strains, the 
epidemiology of circulating swine influenza viruses had remained moderately constant for 
the previous 80 years as mostly drifting classical H1N1 strains (Olsen, 2002).  In the human 
population, numerous sporadic human infections of (H1) triple-reassortant swine influenza 
viruses have been detected since 2005 (Shinde et al., 2009).  In March 2009, a large-scale 
outbreak of a novel influenza A H1N1 triple reassortant virus, most closely related to swine 
influenza viruses, occurred in North America (Dawood et al., 2009; Kerr, 2009).  The 
outbreak of the novel H1N1 virus into the naïve human population has resulted in 53,685 
confirmed infections in over 70 countries and over 302 deaths resulting in a stage 6 pandemic 
as of June 2009 (Kerr, 2009; WHO, 2009).   
 
Viral replication 
The influenza A virus genome is comprised of eight segments encoding 10 to 11 
known protein products; hemagglutinin (HA), neuraminidase (NA), polymerase basic 1 and 2 
(PB1, PB2), polymerase acidic (PA), nucleoprotein (NP), the non-structural (NS) segment 
coding for non-structural 1 (NS1) and non-structural 2 or nuclear export protein (NS2 or NEP 
respectively) proteins, and the matrix (M) segment coding for matrix 1 (M1) and matrix 2 
(M2) proteins.  The 11
th
 protein, PB1-F2, is a non-structural +1 frameshift alternative reading 
frame on the PB1 genomic segment.  PB1-F2 is not present in all influenza A viruses and is 
not required for viral replication or survival. Genomic segments range from 890 to 
approximately 2340 base pairs in length for a total genomic size of ~14 Kb.   
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Initiation of viral replication begins with the association of PB1, PB2, PA and 
ribonucleoprotein (vRNP) to form the viral replication complex.  The error-prone RNA 
replication complex transcribes multiple copies of the viral genome while viral RNA 
segments are translated by host machinery into protein products.  HA, NA, and M2 protein 
products are transported to the cellular surface by the Golgi apparatus and become anchored 
the plasma membrane (Baigent and McCauley, 2003).  At the start of viral packaging, 
genomic segments become closely associated with helical nucleoproteins resulting in vRNP 
complexes prior to being positioned below the membrane anchored HA, NA, and M2 
proteins (Keen, 1995).  The M1 protein associates around the inside of the virion prior to 
budding, becoming chemically bound to the vRNP segments.  M2 functions as an integral 
membrane protein on the influenza virion, forming an ion channel necessary for membrane 
fusion and viral entry into the cell.  Two glycoproteins HA and NA form the only protruding 
elements on the outside of the virion and thus compose the major antigenic elements to host 
viral defenses. As M1 and vRNPs aggregate below the anchored proteins the virion ‘buds’ 
from the surface.  Sialylated progeny virions are cleaved by NA enzymatic activity and 
released into the extracellular space (Baigent and McCauley, 2003).   
 
Mechanism of infection and virulence factors of influenza virus 
Influenza viruses gain entry into the cell by receptor-mediated endocytosis facilitated 
by the viral surface ligand HA.  HA must be cleaved by a trypsin-like protease into two 
segments, HA1 and HA2 (Hampson and Mackenzie, 2006), prior to entry into the cell.  Once 
bound, the influenza virus is encapsulated by an endosome.  The rapid drop in endosomal pH 
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results in a conformational change of the HA protein, initiating viral opening.  HA binds to 
the glycosylated sialic acid receptor in either an -2,3 (avian) or -2,6 (human) linkage 
configuration (Rogers and Paulson, 1983).  Sialic acid receptor linkages are a major 
determinant of host specificity.  Due to the requirement of trypsin-like proteases for HA 
cleavage influenza infection is restricted to the respiratory and intestinal epithelia where 
trypsin like proteases are produced by a variety of cell types (Hampson and Mackenzie, 
2006).  The exception is highly pathogenic avian influenza (HPAI), which possess multiple 
basic residues at the HA cleavage site allowing trypsin independent cleavage and systemic 
influenza infection (de Wit and Fouchier, 2008).  Antibody mediated responses to the HA 
glycoprotein can effectively neutralize influenza infectivity by blocking the receptor 
mediated entry into the host cell (Skehel, 2009).  However, common antibody recognized 
epitopes rapidly evolve in response to immunological pressure to evade pre-existing 
protective antibody driven responses.  Just recently, highly conserved epitopes on the HA 
protein have been identified which have broad neutralizing abilities (Ekiert et al., 2009; Sui 
et al., 2009).  If proven successful across a wide range of circulating strains, neutralizing 
antibodies with broad cross-protection against multiple influenza subtypes would effectively 
diminish the impact of influenza to human and animal health.   
The second major surface glycoprotein, NA, functions to cleave sialic acid motifs 
from the viral surface facilitating release of progeny viruses.  NA sialidase activity promotes 
infectivity in three main ways: (a) by cleaving newly formed virions from sialic acid residues 
on the cell surface, (b) by preventing newly released virions from aggregating to each other, 
and (c) by promoting viral penetration of sialic acid rich mucin which protects the respiratory 
epithelium (Bhatia and Kast, 2007).  To date there are nine NA subtypes identified (Olsen et 
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al., 2006a; Skehel, 2009; Webster et al., 1992).  The NA protein acts as a host determinant by 
its substrate specificity (2,3 or 2,6) and by pH specificity [airway versus. intestinal 
epithelia] (Kobasa et al., 1999; Takahashi et al., 2001).  The targets for NA enzymatic 
cleavage must match the linkages of the HA receptor specificity.  In order for influenza to 
infect a host cell, the HA specificity must match the host sialic acid linkages (2,3 or 2,6) 
expressed on the host cell surface.  If the NA enzymatic cleavage does not recognize the 
same linkages, the virion will not be able to be removed from the host cell surface upon 
budding.  The pH at which NA enzymatic activity is functional is a major host determinant 
between mammalian and avian influenza viruses.  While influenza is typically an upper 
respiratory infection in mammalian species, influenza infection is typified as a gastro-
intestinal infection in avian species.  The lower pH of the gut has been shown to inactivate 
NA function of most human and swine influenza isolates, while avian influenza viruses 
retained NA enzymatic activity (Takahashi et al., 2001). 
Other viral proteins also play important roles in host specificity and virulence, such as 
the PB1, PB2, and PA proteins.  The polymerase proteins PB1, PB2, and PA have all been 
implicated as strong influencers of host range specificity and virulence (Baigent and 
McCauley, 2003).  Specific amino acid alterations on the PB2, PB1, and PA proteins are 
known to affect host specificity, virulence, and transcription efficiency (Hatta et al., 2001; 
Kawaoka et al., 1989; Okazaki et al., 1989).  Amino acid substitutions to elements of the 
polymerase complex can result in viral attenuation or alteration in transcription rate in a 
temperature sensitive manner (Giesendorf et al., 1986; Kawaguchi et al., 2005; Murphy et al., 
1997).  Temperature sensitivity can play a role in host specificity and determine the 
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equilibrium between vRNA (+) and alternative plus-sense RNA (cRNA) transcription rates 
(Dalton et al., 2006).   
The influenza polymerase complex aids in the evasion of host immune recognition 
indirectly by introducing genetic polymorphisms to produce variable progeny viruses, an 
event referred to as genetic drift (Hampson and Mackenzie, 2006).  Genetic mutations 
causing amino acid substitution can alter the antigenic sites of important epitopes, resulting 
in antigenic drift.  Drifting influenza viruses are the chief cause of annual variance in 
circulating strains [epidemics], forcing the continual need to update influenza vaccines.  
Acute changes to the influenza genome are typically a product of reassortment events, known 
as genetic shift, resulting in a dramatically altered influenza virus.  Reassortant viruses can 
potentially emerge when two or more differing strains infect the same cell, allowing the 
genomic segments to be exchanged and packaged in a variety of combinations.  
Reassortment events in intermediate hosts who’s physiology allows the infection of influenza 
viruses from multiple species, such as swine, have a greater potential to generate novel 
viruses exceedingly well fit to replicate in naïve populations (Webby et al., 2000).  Such 
viruses introduced into a naïve population possessing little to no pre-existing protective 
immunity often results in widespread infection with elevated morbidity and mortality; as seen 
by the 1957 and 1968 pandemic human-avian reassortant strains (Webster, 1972; Zhou et al., 
1999) and the 1998 emergence of the H3N2 double (human & swine) and triple (human, 
swine, & avian) reassortant viruses in the US swine population (Olsen, 2002; Olsen et al., 
2006b; Richt et al., 2003; Webby et al., 2000).  Whole influenza viruses can directly cross 
the species barrier, but such events are not commonly detected.   
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Influenza encodes two non-structural proteins, NS1 and PB1-F2, capable of 
regulating host cellular functions.  PB1-F2 acts to induce cell death by permeating the 
mitochondrial membrane (Chanturiya et al., 2004; Chen et al., 2001).  PB1-F2 is encoded by 
a +1 frameshift alternative open reading frame on the PB1 genomic segment encoding for a 
conserved 87 amino acid protein (Chanturiya et al., 2004; Chen et al., 2001).  PB1-F2 
preferentially locates to the mitochondria where it permeates the membrane to monovalent 
cations, chloride, and divalent ions (Chanturiya et al., 2004).  The diffusion of ions and 
chloride results in a loss of membrane potential and the release of cytochrome c (Zamarin et 
al., 2005).  Protein-protein interactions between PB1-F2 and adenine nucleotide translocator 
3 (ANT3) or mitochondrial membrane voltage-dependent anion channel 1 (VDAC1) are 
believed to sensitize the cell to apoptotic signaling (Zamarin et al., 2005).  PB1-F2 
expression is not essential to viral infectivity or replication.  Some influenza viruses do not 
encode a functioning PB1-F2 product, particularly in older swine isolates (Chen et al., 2001).  
However, newer SIV isolates typically express the PB1-F2 fragment.  PB1 is the only 
influenza gene with an altered Kozak sequence lacking either an A or G at the -3 position 
relative to the start codon, suggesting ribosomal scanning initiates translation (Chen et al., 
2001). 
The second and more abundant non-structural protein, NS1, is a multifunctional 
protein required for survival in interferon IFN- competent systems.  NS1 is a splice 
variant of the eighth genomic segment of influenza, sharing a portion of the 5’ terminal and 
the 3’ poly (A) region with NS2 (Lamb and Lai, 1980).  NS1 encodes a 217-278 amino acid 
protein with an RNA-binding N-terminal domain and a C-terminal effector domain.  The 
NS1 protein functions in three main capacities: (1) inhibition of post-transcriptional 
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processing, (2) modulation of host and viral translation, and (3) suppression of host viral 
defenses. 
NS1 utilizes both the RNA binding N-terminal and effector C-terminal domains to 
inhibit post-transcriptional processing of mRNA in many ways: (a) it inhibits the exportation 
of mRNA from the nucleus by binding the poly(A) regions of mRNA (Fortes et al., 1994; 
Qiu and Krug, 1994).  (b) NS1 binds to the 30kD subunit of CPSF (cleavage and 
polyadenylation specificity factor), a critical component of the 3’ processing machinery, 
effectively blocking 3’ cleavage and subsequent polyadenylation of pre-mRNAs (Nemeroff 
et al., 1998).  (c) NS1 also binds to the purine rich stem-bulge structures of the U6 snRNA, a 
required component of the spliceosome (Fortes et al., 1994; Qiu et al., 1995) inhibiting post 
transcriptional processing of pre-mRNAs 
NS1 also alters the translational process within the cell to decrease host mRNA 
translation while up-regulating vRNA translation.  By binding eIF4GI, a required component 
for cap-dependent translation, NS1 facilitates vRNA preferential transcription (Aragon et al., 
2000).  Binding of eIF4GI by NS1 serves two purposes: (1) sequestering eIF4GI inhibits the 
use by cellular components for host mRNA translation and (2) NS1 binds vRNAs via the 5’ 
UTR along with eIF4GI to deliver the two to ribosomes resulting in an enhanced translational 
rate of viral proteins (de la Luna et al., 1995).  Along with the sequestration of eIL4GI, 
influenza infection induces hypophosphorylation of eIF4E resulting in the loss of the eIF-4F 
complex that is required for cap-dependent translation (Feigenblum and Schneider, 1993).  
By the N-terminal RNA binding domain, NS1 binds dsRNA and ssRNA to limit the 
detection by RNA-regulated Protein kinase (PKR).  Detection of viral RNA by PKR activates 
host viral defenses including the phosphorylation of eIF2which decreases the initiation 
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rate of translation (Lu et al., 1995).  NS1 inhibits the activation of PKR by sequestering 
dsRNA and ssRNA, aiding to the aversion of detection by host defenses.  NS1 is also known 
to bind the viral replication complex (Marion et al., 1997) and the cellular multifunctional 
protein nucleolin, involved in ribosome synthesis (Murayama et al., 2007); but the effects of 
these interactions are not clearly known.   
NS1 suppresses cellular immune defenses by (a) by sequestering dsRNA and ssRNA, 
limiting detection by PRR receptors, (b) inhibiting immune signaling by binding signaling 
components, and (c) reducing the translation of host mRNA.  By blocking the processing and 
exportation of cellular mRNA, NS1 is effectively able to suppress the host antiviral response 
by inhibiting the expression of antiviral genes.  The C-terminal effector domain of NS1 also 
binds to the dsRNA sensor, retinoic-acid-inducible gene I (RIG-I), which inhibits activation 
of the IFN- pathway by restricting the RIG-I/IPS-1 mediated IRF-3 signaling cascade 
(Mibayashi et al., 2007).  In addition, by binding ssRNA, NS1 is able to resist detection by 
RIG-I, further inhibiting RIG-I activation of IFN-  and IL-6 expression (Pichlmair et al., 
2006).  As mentioned previously, NS1 binds both dsRNA and ssRNA to limit the detection 
by host cellular defenses.  Pattern recognition receptors on the cellular surface and the 
intracellular matrix such as PKR, melanoma differentiation-associated
 
gene 5 (MDA-5), 
RIG-I, and TLRs (Specifically 7 and 8) all recognize dsRNA and ssRNA to up-regulate host 
immune responses.  By sequestering dsRNA and ssRNA, NS1 inhibits the detection by these 
PRRs, preventing activation of signaling pathways such as OAS (2’-5’ oligo (A) 
synthetase)/RNase L, PKR, NF-kB, NLRP3, IRF-3, and IRF-7 (Garulli and Castrucci, 2009; 
Geiss et al., 2002; Lu et al., 1995; Mibayashi et al., 2007; Min and Krug, 2006; Siren et al., 
2006).   
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Pertinent to this study is the previous research characterizing the H3N2 triple 
reassortant modified live influenza virus (A/swine/Texas/4199-2/98).  Multiple recombinant 
influenza viruses were generated expressing carboxyl-terminal NS1 truncations of variable 
length (Solorzano et al., 2005).  The full-length NS1 gene encoding a 219aa protein was 
truncated to various lengths using restriction enzyme sites, leaving the NS1 gene intact.  
Three virus constructs were generated encoding carboxyl-truncated NS1 proteins of 73, 99, 
and 126 amino acids in length (NS173, NS199, NS1126 respectfully) (Solorzano et al., 
2005).  All other segments of the influenza genome were unaltered.  Initial findings 
demonstrated carboxyl-truncations decreased the capacity of Tx98 to prevent IFN-
expression.  Multicycle growth properties and interferon α/β inhibition assays in 
conjunction with live animal trials showed carboxyl-truncations to the NS-1 protein 
conveyed a level of attenuation inversely dependent on the intensity of interferon α/β 
inhibition.  Surprisingly, the highest level of attenuation resulted from the shortest NS1 
truncation [NS1126 > NS199 > NS173> wtNS1] as measured by macroscopic lung 
lesion scores and virus titer at day 5 post challenge in pigs (Solorzano et al., 2005).  Due to 
its replicative growth properties and attenuation rate in vivo, Tx98 NS1126 was further 
investigated in subsequent trials as a potential influenza MLV vaccine candidate (Richt et al., 
2006; Vincent et al., 2007).  In live animal trials, administration of the H3N2 NS1Δ126 MLV 
administered intranasally provided adequate protection from homologous and homosubtypic 
challenge but only provided limited protective immunity from heterosubtypic challenge 
(Vincent et al., 2007).  The studies contained herein continues on this line of research 
utilizing the previously described Tx98NS1126 MLV in conjunction with recombinant 
porcine IL-18 (rpIL-18) administration to evaluate the potential for broad cross protection 
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against the challenge by a heterosubtypic triple reassortant swine influenza virus [H1N1 
(A/swine/Iowa/00239/2004)] 
 
Protective immunity against influenza infection 
Influenza is an acute respiratory illness often accompanied with secondary bacterial 
infections in severe cases (Brundage, 2006).  Swine influenza is a common component 
contributing to the porcine respiratory disease complex (PRDC) (Baskerville, 1981).  While 
current commercial swine influenza vaccines adequately protect against homologous and 
homosubtypic influenza viruses, they often fail to elicit protective immunity to 
heterosubtypic influenza strains.  While pre-existing antibody is the only known mechanism 
to achieve sterilizing immunity to influenza (Gerhard, 2001), mutations (drift) and 
reassortment events (shift) result in rapid changes to antibody recognized epitopes.  
Inversely, cell mediated immune responses typically recognize more static internal influenza 
proteins possessing conserved epitopes (Doherty et al., 1997; Doherty et al., 2006; Flynn et 
al., 1999; Thomas et al., 2006).   
During an influenza infection, CD4+ T cells primarily function to promote a high-
quality antibody response (Doherty et al., 2006).  CD4+ T cells respond to viral peptides on 
MHC II molecules by induction of cytokine release.  The cytokines have many functions 
including activating inflammatory pathways, stimulating CD4+ and CD8+ proliferation, and 
aiding in the differentiation of T and B cells (Moran et al., 1999).  In an adoptive-transfer 
murine model, naïve CD4+ TCR-transgenic cells exhibited proliferative responses 3 weeks 
past viral clearance in the host (Jelley-Gibbs et al., 2005), indicating that antigen presentation 
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following influenza infection occurs long after viral clearance.  The ultimate nature of the 
CD4+ proliferative response was dependent upon the stage of infection at time of transfer.  
Early adoptive transfers at the height of infection resulted in a strong proliferative response 
resulting in a large primary effector pool, contracting significantly into a small memory 
CD4+ T cell population after viral clearance (Jelley-Gibbs et al., 2005).  Conversely, 
adoptive transfer of naïve CD4 T cells at or after the time of viral clearance resulted in a 
pedestrian proliferative response but sustained a higher ultimate number of CD4+ T cells 
surviving as memory T cells. 
During influenza infection, CD8+ T cells’ main effector function is clearance of virus 
infected cells by Fas (CD69) mediated or perforin and granzyme mediated cytotoxicity 
(Moran et al., 1999; Topham et al., 1997).  Antigen specific memory CD8+ T cells to are 
maintained in high numbers a month or more post primary influenza infection (Flynn et al., 
1999) in a murine model.  Primary effector antigen specific CD8+ T cells were mostly 
cleared by day 15 post primary infection of influenza virus (Flynn et al., 1999).   
Recovery from influenza infection is primarily mediated by cellular immune 
responses (Graham and Braciale, 1997; Topham et al., 1996).  The dominant adaptive 
immune effector functions at the respiratory epithelial layer are secretory IgA (S-IgA) 
antibodies and antigen specific CTLs (Tamura and Kurata, 2004).  While IgG antibodies 
enter the respiratory tract by diffusion at the alveolar epithelia from the serum (Tamura and 
Kurata, 2004), IgA antibodies are transported to the mucosal surface by transepithelial 
transport in dimeric form (Tamura and Kurata, 2004).  It is theorized IgA antibodies can bind 
to intracellular antigen as it is transported through the epithelial cells (Murphy et al., 2008).  
Upon reinfection with influenza, S-IgA and IgG antibodies form virus-immunoglobulin 
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complexes, facilitating neutralization and removal of influenza virus.  Cytokine signaling 
contributes significantly to antibody isotype class switching.  The complement-activating 
IgG2 isotype is the major form generated by B cells in a TH1 environment, whereas classic 
TH2 cytokines typically stimulates the production of the IgG1 non-complement-activating 
isotype (Moran et al., 1999).   
Studies with IL-18 deficient (IL-18 
-/-
) transgenic mice have demonstrated the 
necessity for adequate IL-18 expression to generate optimal protective immunity to influenza 
infection.  IL-18 
-/-
 transgenic mice infected with influenza A virus resulted in (a) viral titers 
reaching maximum at earlier time points, (b) significantly elevated virus titers, (c) 
significantly lower IFN-γ production, and (d) lower activity levels of NK cell-mediated 
cytolysis (Billaut-Mulot et al., 2000; Denton et al., 2007; Dinarello, 1999; Foss et al., 2001; 
Liu et al., 2004; Takeda et al., 1998).  Further research has additionally demonstrated that IL-
18 is required for optimal production of cytokines IFN-γ, TNFα, and IL-2 by CD8+ T cells 
during the course of influenza infection (Denton et al., 2007).   
Broad cross-protection to multiple subtypes of influenza is known to result following 
live influenza infection.  Cross-protection, or heterosubtypic immunity, is not completely 
understood but is believed to be the effect of CD4+ T-cells, of memory CD8+ T-cells 
targeting the conserved internal proteins presented by MHC class I on the host cell surface, 
and by S-IgA and IgG virus neutralization and antibody cross-linking (Benton et al., 2001; 
Graham and Braciale, 1997; Liang et al., 1994; Moran et al., 1999; Nguyen et al., 2000; 
Schulman and Kilbourne, 1965; Tamura and Kurata, 2004; Tamura et al., 2005; Topham et 
al., 1996).  CD8+ T cells tend to target the more conserved influenza proteins NP and M 
(Doherty et al., 1997; Doherty et al., 2006; Flynn et al., 1999; Thomas et al., 2006), allowing 
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broader protection from varying strains and subtypes.  CD8+ T cells from mice immunized 
with H1N1 influenza A virus rapidly proliferated in response to intranasal challenge with an 
H3N2 virus that shares the same immunodominant epitope of the NP protein (Flynn et al., 
1998; Flynn et al., 1999).  B cell deficient mice naïve to influenza have 50-100X greater 
susceptibility to a lethal influenza virus challenge than do wild-type mice.  However, after 
priming mice with a sublethal dose, B cell 
-/- 
mice exhibited an enhanced resistance to lethal 
virus infection compared to wild type controls (Graham and Braciale, 1997), suggesting 
memory CMI responses are efficient mechanisms for influenza viral clearance.   
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Abstract 
Interleukin (IL)-18 is a pleiotropic cytokine participating in a variety of immune 
functions dictated by the surrounding immunological environment.  Characteristically, IL-18 
acts to produce a strong cell mediated immune (CMI) response by activating type II 
interferon signaling; stimulating NK cells, T cells, B cells, and professional APCs to elicit a 
phenotypic TH1 immune response.  Due to the strong induction of CMI by IL-18, it may 
prove to be an advantageous cytokine for the therapeutic enhancement of immune responses 
to vaccination or treatment of disease.  The use of cytokines for therapeutic 
immunomodulation or enhancement of protective immunity has been shown to be 
efficacious.  To generate an enhanced immunomodulatory agent, wild type porcine IL-18 
cDNA was mutated at two amino acid positions, E41A and K88A, to generate an IL-18 with 
increased biological activity.  Mutated and wild type forms of IL-18 were used to generate 
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replication-defective adenoviral expression vectors.  High quantities of rIL-18 (>10ng/mL) 
were generated by adenoviral expression vectors in vitro.  Examination of biological activity 
was inconclusive in vitro and in vivo.  Administration of rIL-18 adenoviral vectors to pigs 
resulted in a consistent up-regulation of IFN- in nasal wash samples for two days following 
inoculation, though protein levels were near the limits of the assay.  Serum IFN- levels did 
not produce consistent results regardless of administration route or treatment. 
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1. Introduction 
Through the course of evolution, innate and adaptive immune systems have 
developed to protect against viral, bacterial, fungal, and parasitic infections.  Prophylactic 
treatments such as vaccinations further reduce the morbidity and mortality associated with 
many diseases.  However, rapidly evolving pathogens and, at times, the development of 
unprotective or inappropriate immune responses continues to provide challenges to the 
human and animal health industries.  Inappropriate or unprotective immune responses can 
develop as a consequence of host genetics, stage of immunological development, pathogen 
derived immunomodulatory agents, or other environmental factors (Fallon and Alcami, 2006; 
Forsthuber et al., 1996; Muneta et al., 2002; Pertmer et al., 2001; Ridge et al., 1996; Siegrist, 
2001).  For example, the neonatal immune system exhibits a range of dysregulated or 
insufficient immune responses including pro-inflammatory pathways and T cell polarization 
(Forsthuber et al., 1996; Pertmer et al., 2001; Ridge et al., 1996; Sarzotti et al., 1996).  In 
neonates, T cells display an impaired ability to polarize towards a phenotypic TH1 based 
immune response (Breathnach et al., 2006; Forsthuber et al., 1996; Pertmer et al., 2001; 
Sarzotti et al., 1996; Siegrist, 2001; Siegrist et al., 1998; Suen et al., 1998). 
Therapeutic treatments, such as cytokine administration, have been able to restore 
correct immune function (Pertmer et al., 2001; Ridge et al., 1996; Siegrist, 2001) or enhance 
protective immunity (Zuckermann et al., 1998).  However, a short half-life in vivo is a 
particular problem concerning the therapeutic administration of recombinant cytokine 
protein.  A plausible solution is to deliver cytokines by vectored gene delivery, capable of 
extended cytokine expression.  Engineered replication-competent and replication-deficient 
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adenoviral expression systems have been shown to be safe and effective (Brockmeier et al., 
2009; Croyle et al., 2008; Mayr et al., 1999; Mayr et al., 2001; Phillpotts et al., 2005; 
Stephenson, 1998; Walter et al., 2001; Xiang and Ertl, 1999).  The use of adenoviruses as 
expression vectors is well established in over 200 clinical trials, two licensed vaccines, and 
numerous studies including HIV, malaria, FMD, yellow fever, rabies, ebola, and influenza 
virus (Croyle et al., 2008; Li et al., 2007; Mayr et al., 1999; Mayr et al., 2001; Patterson et 
al., 2009; Phillpotts et al., 2005; Stephenson, 1998; Tang et al., 2009; Tucker et al., 2008; 
Walter et al., 2001; Xiang and Ertl, 1999; Yang et al., 1994).  Adenoviruses are well suited 
for mucosal administration, including oral and intranasal routes, able to elicit high IgA 
antibody titers and effective CD8+ T cell responses (Croyle et al., 2008; Phillpotts et al., 
2005; Tang et al., 2009; Tucker et al., 2008; Walter et al., 2001; Xiang and Ertl, 1999).  
Specific to veterinary medicine, adenoviral vectors have been utilized to deliver avian 
influenza antigens to vaccinate poultry (Tang et al., 2009), to deliver E2 glycoproteins to 
protect against Venezuelan equine encephalitis virus (Phillpotts et al., 2005), and efficacious 
induction of immunity against foot-and mouth disease virus (FMDV) upon adenoviral-
mediated delivery of the FMDV capsid (P1-2A) or the viral 3C protease (Mayr et al., 1999; 
Mayr et al., 2001). 
Interleukin (IL)-18 may prove to be a particularly useful cytokine for therapeutic 
immunomodulation.  Initially named interferon- inducing factor (IGIF), IL-18 is most 
widely known for its potent ability to up-regulate interferon- (IFN- in the presence of IL-
12, resulting in phenotypic TH1 T cell differentiation and proliferation (Nakamura et al., 
1993).  Acting at the cellular level, IL-18 stimulates macrophages, NK cells, professional 
antigen presenting cells (APCs), T cells and B cells, and is able to up-regulate a host of 
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antiviral, antibacterial, and antifungal associated responses (Kohno et al., 1997; Moran et al., 
1999; Yoshimoto et al., 2000; Yoshimoto and Nakanishi, 2006; Yoshimoto et al., 1997).   
IL-18 is highly regulated at the transcription and protein level.  IL-18 is encoded as a 
biologically inactive precursor (pro-IL-18) requiring cleavage by Interkeukin-1 converting 
enzyme (Caspase-1 or ICE) to become biologically active.  Furthermore, constitutively 
expressed IL-18 binding protein (IL-18BP) acts to neutralize biologically active IL-18 upon 
binding (Novick et al., 1999).  However, unlike most other soluble cytokine receptors, IL-
18BP is not a variant of the IL-18 receptor (IL-18R) and shares no significant homology with 
IL-18R (Novick et al., 1999).  Due to the differences in binding sites between IL-18R and IL-
18BP, amino acid conversions introduced within the IL-18/IL-18BP binding interface of 
human IL-18 (huIL-18) has been reported to yield a longer half-life and enhanced biological 
activity (Kim et al., 2002; Kim et al., 2001). 
To evaluate if synonymous mutations to a porcine IL-18 would result in similar 
increases in biological activity, a comparable mutated IL-18 construct was generated from 
porcine IL-18 cDNA (Genbank accession number U68701).  Using PCR-primer site directed 
mutagenesis, two amino acid conversions (E41A and K88A) were introduced at critical 
amino acid sites for IL-18BP neutralization.  For each rIL-18 construct, two different Kozak 
sequences were used (GCCACCATGG[E] or GCCGCCGCCATGG [F]) to evaluate optimal 
expression of rIL-18 (wtIL-18E, wtIL-18F, mutIL-18E, and mutIL-8F).  Using a replication-
defective adenovirus expression system (AdEasy™ XL System (Stratagene, La Jolla, CA)), 
adenovirus vectors expressing wtIL-18 or mutIL-18 were generated.  Recovered rIL-18 
adenoviral isolates were sequenced to confirm desired mutations and Kozak sequences 
(Figure 2.2).  Adenoviral vectors were evaluated for biological expression of recombinant IL-
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18 (rIL-18) and the resulting IL-18 was assessed for biological activity both in vitro and in 
vivo. 
 
2. Materials and Methods 
2.1 Cells 
AD-HEK-293 cells were cultured in Dulbecco's Modified Eagles Medium high glucose 1X 
with 4.5g/L D-glucose, L-Glutamine, 110mg/L sodium pyruvate, supplemented with 2-10% 
fetal bovine serum, 100 units/L of penicillin, 100 µg/L of streptomycin, and 2.5 µg/L of 
amphotericin B, streptomycin sulfate, and amphotericin B Antimycotic; all from Gibco 
(Marketed by Invitrogen, Grand Island, NY).   
Peripheral blood mononuclear cells were isolated from porcine whole blood by 
Vacutainer CPT™ sodium citrate separation tubes or by percoll method (Ulmer et al., 1984) 
treated with 2X acid citrate dextrose (ACD).  PBMCs were sustained in RPMI 1640 media 
containing L-glutamine and 25mM HEPES, supplemented with 10% fetal bovine serum, 100 
units of penicillin, 100 µg of streptomycin, and 0.25 µg of amphotericin B/ml utilizing 
penicillin G (sodium salt), streptomycin sulfate, and amphotericin B Antimycotic; all from 
Gibco (Marketed by Invitrogen, Grand Island, NY). 
 
2.2 Mutagenesis of porcine IL-18 
Dual point mutations were introduced into a porcine wild type IL-18 encoding cDNA 
construct by PCR primer site-directed mutagenesis.  Two sets of PCR primers were designed 
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to individually introduce amino acid conversions at positions 41 (E to A) and 88 (K to A).  
Mutations and full-length sequence fidelity were confirmed by sequencing (Figure 2.1).  The 
mutIL-18 plasmid was previously generated within our lab by Ma et al. (unpublished data).  
 
2.3 Addition of Kozak initiation sequence to rIL-18 cDNA 
PCR primers were used to incorporate two different Kozak sequences 
(GCCACCATGG (E) or GCCGCCATGG (F)) to each form of IL-18, generating four cDNA 
constructs (wtIL-18E, wtIL-18F, mutIL-18E, and mutIL-18F).  Restriction enzyme cutting 
sites were also introduced directly outside the ORF to be utilized for directional cloning in 
downstream procedures.   
Forward 5’ primer: E 
5’ATCATTACAGATCTGCCACCATGGCTGCTGAACCGGAAG3’ 
                          Bgl II            Kozak                   IL-18 Sequence  
Forward 5’ primer: F 
5’ATCATATTAGATCTGCCGCCGCCATGGCTGCTGAACCG3’ 
                          Bgl II                Kozak                   IL-18 Sequence  
Reverse Primer: R 
5’ATACTCATCTCGAGCTAGTTCTTGTTTTGAACAGTGAACATTATAG3’ 
                         Xho I       Stop            IL-18 Sequence  
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2.4 Generation of replication defective adenoviruses (wt & mutIL-18) 
Adenoviral expression vectors were constructed using the AdEasy™ XL System 
(Stratagene, La Jolla, CA) as described in the AdEASY™ vector system manual (v1.4 Q 
BIOgene, Carlsbad, CA).  In short, cDNA constructs were directionally cloned into a transfer 
vector (pShuttle), introducing a promoter from the immediate early (IE) region of the 
cytomegalovirus (CMV) and a simian virus 40 polyadenylation signal.  pShuttle-CMV-IL-18 
constructs were then transformed into One Shot® Top10® electrocompetent cells 
(Invitrogen, Grand Island, NY) for large DNA preparations.  Transformed cells were 
screened by antibiotic resistance and positive colonies were further screened for retention of 
correct insertion by restriction enzyme digestion and DNA gel electrophoresis.  Preparations 
of positive isolate colonies were subsequently grown in 5mL LB/ kanamycin, DNA purified, 
and resulting plasmids linearized by RE digestion prior to transformation into RecA+ 
BJ5183-AD-1 electroporation competent cells, pre-transformed with the replication defective 
human adenovirus-5 vector plasmid pAdEasy-1 (huAd5ΔE1ΔE3).  Positive recombinants 
were screened and prepared as stated previously prior to transformation into XL10-Gold™ 
ultra-competent cells for large DNA preparations.  Selected colonies were prepared using a 
SNAP Midiprep Kit (Invitrogen, Grand Island, NY).  DNA from the SNAP preparations was 
lipotransfected into HEK293 cells per manufacturer’s protocol for Lipofectamine 2000 
(Invitrogen, Grand Island, NY).  Isolated, well developed plaques were collected following 
the procedure outlined in the AdEasy Adenoviral Vector System manual.  Several rpHuAd5 
vector clones were selected for each IL-18 construct and sequenced to confirm correct 
insertion, Kozak sequence, and desired porcine IL-18 sequence.   
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2.5 Virus   
Low passage replication deficient adenovirus isolates expressing wtIL-18 and mutIL-
18 were propagated in specialized AD-HEK-293 cells genetically altered to support 
replication.  For use as inocula, adenovirus isolates were purified and concentrated by double 
CsCl density gradients as described in the AdEasy™ vector system manual (v1.4 Q BIOgene, 
Carlsbad, CA).  In short, 40 T150 cell culture flasks (Corning, Corning, NY) were inoculated 
per virus.  Samples were collected when CPE had reached 100%.  Media was consolidated 
and spun at 300 rcf for 10 min to obtain a single cell pellet, discarding the supernatant.  
Pellets were freeze/thawed three times to lyse cells and release the virus.  Discontinuous 
gradients (1.4-1.2 CsCl sp gr) were prepared in 50mL ultracentrifuge tubes. Samples were 
overlaid on top of discontinuous gradient and centrifuged at 100,000 rcf for 90 minutes.  
Concentrated adenovirus was collected by aspiration of the adenoviral band and immediately 
overlaid on previously prepared continuous gradients (1.4-1.2 CsCl sp gr) and spun at 
100,000 rcf for 20-24 hours.  Resulting concentrated adenoviruses were desalted by dialysis 
in 10mM Tris (pH 8.0), 2mM MgCl2, 4% sucrose buffer.  Purified adenoviral isolates were 
titered by tissue culture infectious dose 50% [TCID50/mL] as described in the AdEasy™ 
vector system manual.  Adenoviral inoculums were diluted to 1.0 X 10
9
 TCID50/mL in sterile 
PBS shortly before administration.   
 
2.6 In vitro biological expression of rIL-18 
To confirm rIL-18 expression by adenoviral vectors, AD-HEK-293 cells were 
inoculated as an approximate MOI of 200 and allowed to progress for various time points.  
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Prior to rIL-18 measurement, samples were freeze/thawed a total of three times for optimal 
release of intracellular rIL-18 (data not shown).  rIL-18 protein levels of freeze/thawed (F/T) 
supernatants were measured in duplicate using an enzyme-linked immunosorbent assay 
(ELISA) for swine IL-18 (Invitrogen, Grand Island, NY) per manufacturer’s instructions. 
 
2.7 In vitro biological activity assay 
Biological activity of rIL-18 was evaluated by porcine PBMC responsiveness to rIL-
18 treatment as measured by IFN- up-regulation.  rIL-18 preparations were generated in 
AD-HEK-293 cells at varying media concentrations.  Resulting supernatants were F/T 3X 
prior to centrifugation at 300 rcf for 5 minutes to remove large cellular debris.   
Concentrated rIL-18 supernatants were prepared by inoculating 10 nearly confluent 
T150 flasks (AD-HEK-293) per adenoviral construct.  When cells reached a CPE of 90-
100% samples were F/T a total of three times to release intracellular rIL-18 protein.  Samples 
were spun at 300 rcf for 5min and resulting supernatants were vacuum filtered (0.2μm) to 
remove large cellular debris.  100kD and 10 kD (Millipore Corp., MA, USA) centrifugal 
filter units were used to further filter and concentrate the rIL-18 supernatant.  Measurements 
of resulting rIL-18 concentrates were performed in duplicate using a swine IL-18 ELISA per 
manufacturer’s instructions.  
Biological activity assays were performed at a range of PBMC concentrations per 
cm
2
, PBMC isolation methods, co-stimulatory agents, and rIL-18 preparation methods to find 
the optimal parameters.  rIL-18 stimulated PBMCs were incubated at 39
°
C, 5% CO2 for the 
duration of each time point.  Samples were F/T a total of three times to release intracellular 
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IFN-prior to IFN- protein quantitation.  The IFN-protein concentration present in each 
PBMC supernatant was measured in duplicate by swine IFN- ELISA per manufacturer’s 
instructions (Invitrogen, Grand Island, NY). 
A single wild type rIL-18 expressing adenovirus construct was used as a wild type 
control.  Based on preliminary analysis, the wtIL-18 construct Ad5+wtIL-18K:E containing 
the E Kozak sequence displayed the highest biological activity and was therefore chosen.  
The wild type rIL-18 construct (Ad5+wtIL-18K:E) was previously generated by Kehrli et al. 
(unpublished data).  A replication defective adenovirus null vector (Ad5B), expressing a 
galactosidase  gene fragment was used as an adenoviral control vector (Moraes et al., 
2001). 
 
2.8 Virus titration 
Titration of adenovirus samples was calculated as the tissue culture infectious dose 
50% (TCID50) as described in AdEASY™ vector system manual (v1.4 Q BIOgene, Carlsbad, 
CA).  In short, 1X10
4
AD-HEK-293 cells were plated per well in a 96-well plate and were 
allowed to adhere for 1 hour.  10-fold serial dilutions of each adenovirus sample from 10
-1
 to 
10
-11 
were administered at 100μL per well in a replicate of eight.  Plates were incubated at 
37
°
C and 5% CO
2 
for 12 days.  On day 12, plates were scored for CPE in each row and 
TCID50 calculated by the formula:  
TCID50/mL =10
1+d(s-0.5) 
* 10, d=Log10 (dilution), s= sum of ratios 
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2.9 In vivo biological activity assay 
Comparison of biological activity of wild type IL-18 verses mutated IL-18 constructs 
were evaluated in vivo by intramuscular (IM) and intranasal (IN) routes of administration.  
Thirty pigs were delivered at two weeks of age and were randomly separated into five groups 
of five after being treated with a single dose of EXCEDE™ (Ceftiofur Crystalline) per 
manufacturer’s recommend dose.  Pigs were housed for two weeks prior to start of study.  
Treatment groups and routes of administration were structured as described in Table 2.1. 
Table 2.1  In vivo rIL-18 biological activity assay treatment group outline 
Group Room N Treatment Group
1 1 5 Ad5+wtIL-18K:E - IN route
2 1 5 Ad5+wtIL-18K:E - IMroute
3 2 5 Ad5+mutIL-18K:E3 - IN route
4 2 5 Ad5+mutIL-18K:E3 - IM route
5 3 5 Vector Control (Ad5B) - IM rotue
6 4 5 Negative Sham: IM  
 
Adenovirus stocks purified by double CsCl gradients were diluted to an approximate 
titer of 1.0 X 10
9
 TCID50/mL in sterile PBS for use as animal inocula.  Sterile PBS was used 
as the sham inoculum.  Inocula were administered in 2 mL doses either intranasally (IN), by 
slowly dripping into the nose, or intramuscularly (IM).  Nasal washes and serum samples 
were collected from day 0 to 5 days post vaccination (dpv).  Measurement of IFN- protein 
levels within nasal wash and serum samples were evaluated by swine IFN- ELISA 
(Invitrogen, Grand Island, NY). 
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3. Results 
3.1 Generation of mutated porcine IL-18 by site-specific mutagenesis 
Mutations to wild type porcine IL-18 cDNA:  Two amino acid conversions were 
introduced into the wild type porcine IL-18 gene at amino acid positions 41 and 88.  
Glutamic acid (E) at position 41 and lysine (K) at position 88 were converted to alanine by 
site directed mutagenesis.  Both glutamic acid and lysine possess hydrophilic, charged R 
groups which are predicted by computer modeling to be involved in binding to the inhibitory 
IL-18BP (Kim et al., 2002).  Alteration at these positions to alanine induced extended half-
life and heightened biological activity in human IL-18 (Kim et al., 2001).  Sequencing 
confirmed desired mutations in the mutIL-18 cDNA (Fig. 2.1). 
Figure 2.1  Amino acid alterations: mutIL-18 vs. wtIL-18  
 
Fig. 2.1.  Sequence analysis of site-directed mutagenesis to porcine IL-18 cDNA at amino acid positions 41 and 88.  
 
Addition of differing Kozak sequences per rIL-18 cDNA construct:  Two 
different Kozak sequences were used (GCCACCATGG [E] or GCCGCCGCCATGG [F]) for 
each form of IL-18 to evaluate optimal expression of rIL-18.  Forward primers arbitrarily 
designated E (38mer) or F (39mer) were used with a single IL-18 reverse primer (R) to 
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introduce desired Kozak sequences into wtIL-18 and mutIL-18 genes by PCR.  The four 
resulting cDNA constructs [wtIL-18K:F, wtIL-18K:E, mutIL-18K:E, and mutIL-18K:F] 
were sequenced to confirm correct Kozak sequences (Fig. 2.2).   
Figure 2.2  Kozak sequence comparison: mutIL-18 E & F, wtIL-18 E & F 
 
Fig. 2.2.  Sequence analysis of Kozak sequences E & F for both mutated and wild type rIL-18 cDNA plasmids.   
 
3.2 Generation of rIL-18 adenoviral vectors 
Generation of replication-defective rIL-18 adenoviral vectors:  Adenoviral 
vectors expressing either wild type or mutated forms of IL-18 were generated using the 
AdEasy™ XL System (Stratagene, La Jolla, CA).  Recombinant wild type and mutated forms 
of IL-18 of each Kozak sequence were directionally cloned into the pShuttle-CMV plasmid, 
introducing a promoter from the immediate early (IE) region of the cytomegalovirus (CMV) 
and a simian virus 40 polyadenylation signal to induce high level expression.  rIL-18 
constructs were combined with the replication defective human adenovirus-5 plasmid, 
pAdEasy-1 (huAd5ΔE1ΔE3), by homologous recombination in RecA+ BJ5183-AD-1 
electroporation competent cells.  Resulting plasmids were lipotransfected into AD-HEK-293 
cells genetically modified to support the replication of the adenoviral vectors.  Several clones 
of each adenoviral construct [Ad5+mutIL-18K:E, Ad5+mutIL-18K:F, Ad5+wtIL-18K:E, 
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Ad5+wtIL-18K:F] were collected from well developed plaques following the procedure 
outlined in the AdEasy adenoviral vector system manual.  Selected clones were sequenced to 
confirm correct insertion, Kozak sequences, and sequence homology.  Ad5+mutIL-18K:F1 & 
F2, clonal isolates from the homologous recombination step, are shown to possess a single 
frameshift nucleotide insertion 12 base pairs upstream of the termination codon.  To evaluate 
the differences between mutIL-18 and wtIL-18 in downstream assays, a single wtIL-18 
adenoviral construct [Ad5+wtIL-18K:E] was used.   
 
3.3 In vitro expression of rIL-18 in vitro  
Conformation of adenoviral-mediated rIL-18 expression:  Eight mutIL-18 
adenoviral isolates (Ad5+mutIL-18K:E 1-4 & Ad5+mutIL-18K:F 1-4) were evaluated in 
relation to a single wild type rIL-18 adenoviral construct (Ad5+wtIL-18K:E) to assess 
biological expression of rIL-18.  AD-HEK-293 cells were inoculated and the adenovirus 
infection was allowed to progress for selected time points.  At the completion of each time 
point, cells were F/T 3X to release intracellular IL-18 protein prior to measurement of 
supernatants by swine IL-18 enzyme-linked immunosorbent assay (ELISA).  
Pharmacokinetic studies have found the half-life (t1/2) of human IL-18 to be 35 hours 
(Robertson et al., 2006) and 16 hours for murine IL-18 (Hosohara et al., 2002).  Based upon 
the previous pharmacokinetic studies, a 12-hour time point was chosen to account for a 
possible shorter half-life of porcine IL-18.   
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Figure 2.3  Biological expression analysis of rIL-18 adenovirus vectors 
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Fig. 2.3.  IL-18 (pg/mL) protein expression of adenoviral constructs as measured by swine IL-18 ELISA.  Supernatants of 
AD-HEK-293 cells were collected at 12-hour intervals.  Results are reported as means ± SE from three independent trials.  
Differences between treatment groups were not statistically significant [Two-way ANOVA (P>0.05)] 
 
In three independent trials, expression of rIL-18 protein was confirmed from all 
adenoviral isolates except for the negative control (Fig. 2.3).  All rIL-18 positive isolates 
produced at or above 500 pg/mL and up to 1000 pg/mL of rIL-18 protein under the 
conditions tested.  Analysis between all groups, for all time points, by Two-way ANOVA 
analysis showed no statistical differences between groups (P>0.05). 
 
Kozak sequence and rIL-18 expression levels:  The Kozak sequence is defined in 
relation to the adenine nucleotide of the start codon (+1), ranging from -9 to +4 with a 
general consensus sequence of (gcc)gccRccAUGG (Kozak, 1984, 1987); R is defined as a 
purine.  Changes from a ‘strong’ to a ‘weak’ Kozak consensus sequence can result in greater 
than 20 fold differences in the level of protein translated (Iida and Masuda, 1996; Kozak, 
1984, 1986, 1987).   
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Figure 2.4  Biological expression analysis of mutIL-18 expression by Kozak sequence 
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Fig. 2.4.  To evaluate the differences in rates of protein translation conveyed by Kozak sequence, in vitro biological 
expression data in AD-HEK-293 cells from the mutIL-18 E & F groups were consolidated from three independent trials 
[Ad5+mutIL-18K:E1-4, Ad5+mutIL-18K:F1-4].  Results are reported as group means ± SE.  Differences between groups 
were not statistically significant as calculated by Two-way ANOVA analysis (P>0.05). 
 
To design an optimal rIL-18 expression vector, two characteristically ‘strong’ Kozak 
sequences were used with each form of IL-18 to evaluate optimal expression.  The Kozak 
sequence designated [F] is comprised of an extra (gcc) nucleotide sequence at positions -9 to 
-7, and a guanine nucleotide at position -3, to make a theoretically stronger Kozak sequence 
compared to [E] (De Angioletti et al., 2004; Kozak, 1987).  To evaluate if the difference in 
Kozak sequence significantly affected the rate of protein translation, the biological 
expression data was reevaluated based upon Kozak sequence (Fig. 2.4).  Results are reported 
as group means ± SE from three independent trials.  Adenoviral vectors containing the [F] 
Kozak sequence did express slightly higher rIL-18 protein on average from 12-36 hours post 
inoculation (p.i.).  However, the differences in expression levels between E and F Kozak 
groups were not found to be significant [Two-way ANOVA (P>0.05)].   
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3.4 Biological activity of rIL-18 in vitro  
Primary biologcial activity assays were conducted utilizing rIL-18 protein generated 
under typical inoculation conditions (18mL per 75cm
2
) yeilding 0.2-0.3 ng/mL rIL-18 
protein concentrations.  The highest rIL-18 expressing adenovirus constructs for each Kozak 
group [E (Ad5+mutIL-18K:E3) and F  (Ad5+mutIL-18K:F2)] was chosen as test isolates.  
Adenoviral isolates Ad5+wtIL-18K:E and Ad5B were used as the wild type rIL-18 control 
and null vector control respectivley.  Concanavalin A (Con A) was used as a positive control 
(0.5-2.5μg/mL).  rIL-18 treated PMBCs or whole blood yeilded no measureable interferon- 
(IFN-) protein from adenoviral supernatants.  In all trials the positive control induced 
measureable IFN- protein expression up to 160 ng/mL in PBMCs and 18 ng/mL in whole 
blood.  Conclusions from the first trials, along with previous published findings, suggested 
higher rIL-18 protien levels are needed to induce a measureable IFN- response in vitro.   
 
Low volume rIL-18 preparations and co-stimulatory agents:  Previous studies 
evaluating the biological activity of rIL-18 reported concentrating rIL-18 protein to high 
quanities (≥100ng/mL) prior to the evaluation of biological activity (Muneta et al., 2000; 
Nagaya et al., 2004), as well as the use of co-stimulatory agents anti-CD3, Con A, IL-2, or 
IL-12 (Munder et al., 1998; Muneta et al., 2000; Nagaya et al., 2004; Nakamura et al., 1993; 
Ushio et al., 1996; Yoshimoto et al., 1998).  To generate higher yeilding rIL-18 products, the 
volume of media used to generate the rIL-18 supernatants was reduced greater than 3 fold.  
Reduction in inoculation volumes yeilded appreciably higher rIL-18 quantities (Fig. 2.5).   
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Figure 2.5  Concentration of rIL-18 yielded by reduced volume culturing conditions 
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Fig. 2.5.  To generate higher yielding IL-18 supernatants, inoculation media volumes were reduced >3-fold (5ml per 75 
cm2).  Supernatants from low volume preparations were measured in duplicate by swine IL-18 ELISA.  Values are reported 
as IL-18 protein (pg/mL) concentrations in the vertical axis by adenoviral isolate.   
 
Biological activity of rIL-18 was reevaluated with the low volume rIL-18 
preparations in the presence of co-stimulatory agents Con A and recombinant porcine IL-12 
(rpIL-18) (Fig. 2.6).  PBMCs were obtained from four pigs by Vacutainer CPT™ separation 
tubes.  PBMCs were diluted to final concentrations of aproximately 4.0 X 10
5
 PBMC/mL or 
2.6 X 10
5
 cells/cm
2 in Con A (1 μg/mL) / rpIL-18 (180ng/mL) media and 0.5mL added to 
each well.  Low volume preparations of Ad5B, Ad5+wtIL-18K:E, and Ad5+mutIL-18K:E3 
were administered at 0.25mL per respective well, resulting in final rIL-18 concentrations of 
Ad5B (0 ng/mL), wtIL-18 (3.6 ng/mL), or mutIL-18 (3.7 ng/mL).  Plain media (0.25mL 
RPMI 1640) was used for the Con A/rpIL-12 media control wells.  Samples were F/T 3X 
prior to measuring in duplicate by swine IFN- ELISA. 
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Figure 2.6  Biological activity evaluation of rIL-18 (Con A/rpIL-12 co-stimulation):  
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Fig. 2.6.  Production of IFN- (pg/mL) by PBMCs treated with low volume rIL-18 preparations.  PBMCs were stimulated in 
the presence Con A (1 μg/mL) and rpIL-18 (180ng/mL) co-stimulation.  PBMC supernatant samples were measured in 
duplicate by swine IFN- ELISA.  Values are reported as mean ± SE from 4 pigs. 
 
 While the wtIL-18 treatment group failed to induce IFN- protein expression past 
backgound levels at any time point, the Con A/rpIL-12 control group exibited a highly 
elevated concentration of IFN- at the 48 hour time point.  The appreciable increase in the 
mean IFN- protein concentration at 48 hours in the Con A/rpIL-12 media control group can 
be attributed to a single sample, while all others were at or below 6.0 pg/mL IFN-.  Only the 
mutIL-18 treatment group induced expression of IFN-above background consistantly across 
time points past 12 hours.   
 
Concentration of rIL-18 by molecular weight exclusion columns:  To account for 
the possible unknown activity of virus and cellular products in the supernatant, a series of 
filtration steps were developed to purify and concentrate rIL-18 supernatants based on size 
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exclusion.  Experimental proceedures were developed from previous studies on recombinant 
porcine IL-18 conducted by Muenta et al. (Muneta et al., 2000).   
For each adenoviral isolate to be tested, AD-HEK-293 monolayers totaling 600 cm
2
 
were inoculated.  At 100% CPE, cell supernatants were F/T 3X and subsequently centrifuged 
at 300 rcf for 5 minutes.  Resulting supernatants were filtered (0.2μM) to remove high 
molecular weight cellular material not removed by the initial centrifugation.  Samples were 
then passed through 100kD centrifugal filtration units (Millipore Corp., MA, USA) to 
remove virus and cellular products larger than ~100kD.  Finally, 10kD centrifugal filtration 
units were used to concentrate the rIL-18 10-fold and remove low molecular weight 
compounds (<10kD).  Resulting rIL-18 concentrates were measured in duplicate by swine 
IL-18 ELISA (Fig. 2.7-2.10). 
Evaluation of concentrated rIL-18 protein preparations for biological activity was 
conducted under three experimental conditions, (a) no co-stimulation, (b) Con A (2.5g/mL) 
co stimulation, or (c) rpIL-12 (100ng/mL) co-stimuation.  PBMCs were isolated from four 
pigs by CPT and were aliquated at 1.0 X 10
6
 PBMC/cm
2
 or 2.0 X 10
6
 PMBC/well.  Time 
points were plated separately and collected at 24 hour intervals for five days.   
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Figure 2.7  IL-18 (pg/mL): 
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Figure 2.8  IL-18 (pg/mL): 
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Figure 2.9  IL-18 (pg/mL): 
Concentrated Ad5+mutIL-18K:E3 
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Figure 2.10  IL-18 (pg/mL): 
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Fig. 2.7-2.10.  Large volume preparations of Ad5B, Ad5+wtIL-18K:E, Ad5+mutIL-18K:E, and Ad5+mutIL-18K:F were 
concentrated 10-fold by centrifugal molecular weight exclusion colums.  Resulting IL-18 (pg/mL) concentrations from the 
concentrated protein preparations were evaluated by swine IL-18 ELISA.   
 
Biological activity of concentrated rIL-18 preparations in the absence of co-
stimulation failed to induce measureable IFN-production in all but one of the four pigs 
(data not shown).  The single responding subject did not produce any detectable IFN- 
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protein until 96 hours post vaccination (<0.074ng/mL).  Conversely, Co-stimulation with 
Con A at 2.5g/mL resulted in a complete exaustion of all PBMC samples by 24 hours; 
exhibiting deteriorating levels of IFN-concentrations as time points progressed past the 
initaial measurement (data not shown).   
Figure 2.11  Biological activity assessment of rIL-18 (rpIL-12 co-stimulation):  
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Fig. 2.11.  Production of IFN- (pg/mL) by PBMCs treated with concentrated rIL-18 preparations.  PBMCs were stimulated 
in the presence rpIL-18 (100ng/mL) co-stimulation.  PBMC supernatant samples were measured in duplicate by swine IFN- 
ELISA.  Values are reported as mean ± SE from 4 pigs. 
 
IFN- induced expression by rIL-18 treatments in the presence of 100ng/mL rpIL-12 
were detectable to quantities greater than 1.5 ng/mL as measured by swine IFN- ELISA 
(Fig. 2.11).  The mutIL-18 treatment groups exhibited elevated IFN-protein concentrations 
compared to the wtIL-18 treatment group.  However, the Ad5B vector control group also 
produced elevated levels of IFN-production when assessed in relation to wtIL-18 past 48 
hours.   
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Figure 2.12  IFN- expression in relation to the negative control group (Ad5B) by 
concentrated rIL-18 protein preparations (rpIL-12 co-stimulation) 
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Fig. 2.12.  IFN- (pg/mL) concentration of rIL-18 treatment groups in relation to the negative control group (Ad5B).  At 
each time point, each measurement was subtracted from the Ad5B measurement per respective pig and time point.  
Corrected values were reevaluated by calculating the mean of four pigs for each treatment group.  Differences between all 
treatment groups by time point are statistically significant [Two-way ANOVA (P<0.05)].   
 
As seen in Figure 2.11, the standard error of mean values was high regardless of time 
point or treatment.  This was the result of a high degree of variability between pigs.  
However, the relative responses to each treatment group from individual pigs were 
consistent.  As the high degree of variability was most notably between pigs and not between 
treatment groups, each sample measurement was subtracted from their negative control group 
per respective pig per time point to control for the variability between pigs (ex. [Pig 1 24h 
Ad5+mutIL-18K:F2] – [Pig 1 24h Ad5B]).  The means ± SE (n=4) of the adjusted values are 
reported in Figure 2.12.  Both mutIL-18 treatment groups (Ad5+mutIL-18K:F2 & 
Ad5+mutIL-18K:E3) exhibited higher IFN- concentrations in comparison to either the 
negative control group or the wild type rIL-18 treatment groups.  Differences between 
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adjusted rIL-18 groups by time point were statistically significant (P>0.05) as calculated by 
Two-way ANOVA analysis.   
 
3.5 Biological activity of adenoviral mediated rIL-18 expression in vivo 
Figure 2.13  In vivo biological activity assessment:  Serum IFN- protein levels by 
treatment group 
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Fig. 2.12.  Adenoviral inocula prepared by double CsCl gradients were administered by either intranasal (IN) or 
intramuscular (IM) route.  Serum concentrations of IFN- protein (pg/mL) were measured by swine IFN- ELISA.  Values 
are reported as group means ± SE (n=5).  Differences between groups were not significant as calculated by Two-way 
ANOVA analysis (P>0.05).   
 
To evaluate the biological activity of rIL-18 in vivo, wild type [Ad5+wtIL-18K:E] 
and mutated [Ad5+mutIL-18K:E3 ] rIL-18 expressing adenovirus constructs were compared 
by intramuscular and intranasal routes of administration in four week old pigs (treatment 
outline Table 2.1).  Nasal wash and serum samples were collected at 24 hour intervals from 
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the day of inoculation to five days p.i..  IFN- protein concentrations were measured in the 
nasal wash and serum samples from each pig by swine IFN- ELISA (Fig. 2.12-2.13). 
Figure 2.14  In vivo biological activity assessment:  Nasal wash IFN- protein 
concentrations by treatment group 
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Fig 2.13.  Adenoviral inocula prepared by double CsCl gradients were administered by intranasal (IN) or intramuscular (IM) 
route.  Concentrations of IFN- protein (pg/mL) from nasal wash samples were measured by swine IFN- ELISA.  Values 
are reported as group means ± SE (n=5).   
 
IFN- expression in response to treatment in vivo:  The quantity of IFN- protein 
detected within the serum samples were generally below the limits of the assay (Fig. 2.12).  
Positive measurements for IFN- protein within serum samples were sporadic and 
inconclusive regardless of administration route or treatment.   
Induction of IFN- protein production was more evident within nasal washes.  IFN- 
protein detected in samples from nasal washes produced consistent results in both rIL-18 
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treatment groups administered by IM and IN (Fig. 2.14).  Groups receiving rIL-18 adenoviral 
vectors (Ad5+wtIL-18K:E IM & IN, Ad5+mutIL-18K:E3 IM & IN) displayed a general 
increase in IFN- protein levels for the two days after inoculation followed by a steep decline 
in IFN- levels on day three p.i..  Levels of IFN-protein were at or below the limits of 
detection of the swine IFN- ELISA.  Control groups also exhibited detectable levels of IFN-
 production. 
 
4. Discussion 
 Previous research conducted by Kim et al. (2001) on huIL-18 as shown site-
specific mutations altering charged residues E42A and K89A resulted in increased biological 
activity.  The amino acid conversions rendered the mutated huIL-18 protein fully resistant to 
neutralization by IL-18BP, extending the half life and enhancing the biological activity of IL-
18 4-fold (Kim et al., 2001).  To evaluate if homologous mutations to porcine IL-18 would 
result in similar increases in biological activity, the amino acid conversions E41A & K88A 
were introduced by PCR-primer site directed mutagenesis to a wild type porcine IL-18 
cDNA construct (Fig. 2.1).   
WtIL-18 and mutIL-18 genes were placed under the control of a CMV promoter and 
strong Kozak sequences prior to insertion into the replication defective adenoviral expression 
vectors.  Testing by swine IL-18 ELISA at various time points confirmed biological 
expression of IL-18 protein by all adenovirus+ rIL-18 test isolates (Fig. 2.3-2.5).  The 
negative control vector Ad5B, containing a LacZ insertion (Moraes et al., 2001), failed to 
induce detectable levels of IL-18 protein in vitro.  Adenoviral isolates expressing rIL-18 were 
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shown to produce high concentrations (>10ng/mL) of rIL-18 protein when cultured in 
reduced volumes (Fig. 2.5).   
Two Kozak sequences were used for each form of IL-18 to evaluate optimal 
expression (Fig. 2.2 & 2.4).  A Kozak sequence is defined in relation to the adenine 
nucleotide of the start codon (+1), ranging from -9 to +4, with the general consensus of 
(gcc)gccRccAUGG (Kozak, 1984, 1987).  Alterations to the Kozak consensus can produce a 
‘strong’ to ‘weak’ initiator sequence resulting in greater than 20 fold difference in protein 
expression (Iida and Masuda, 1996; Kozak, 1984, 1986, 1987).  Although both Kozak  [E] & 
[F] are classified as strong initiator sequences, Kozak [F] is comprised of an extra (gcc) 
sequence at positions -9 to -7, and a guanine nucleotide at position -3, making a theoretically 
stronger Kozak sequence (De Angioletti et al., 2004; Kozak, 1987).  To evaluate expressional 
differences between Kozaks [E] and [F], in vitro biological expression of mutIL-18 isolates 
was reviewed based upon Kozak sequence (Fig. 2.4).  The ‘stronger’ Kozak sequence [F] 
exhibited slightly higher expression of rIL-18 in relation to Kozak [E], although not by a 
statistically significant margin. 
Biological activity of rIL-18 protein was measured as the capacity to induce IFN- 
expression upon administration to swine PBMCs.  In vitro, primary trials utilizing low 
concentrations of rIL-18 (<1ng/mL) in the absence of co-stimulatory agents were unable to 
induce detectable IFN- protein expression.  However, the addition of co-stimulatory agents 
Con A and rpIL-12 with higher yielding low volume rIL-18 preparations resulted in 
detectable levels of IFN- production by porcine PBMCs (Fig. 2.6).  Only the mutIL-18 
treatment group (Ad5+mutIL-18K:E3) induced IFN- protein levels appreciably above the 
negative controls consistently throughout the experiment.  The Con A/rpIL-12 media control 
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group also displayed a considerably elevated concentration of IFN- at the latest time point 
(48 hours).  The aberrant elevation in the IFN- concentration of the Con A/rpIL-12 media 
control group can be attributed to a single sample (140pg/mL) at 48 hours, while all others 
within that group were less than 6.0 pg/mL.   
Similar findings were noted in biological activity assays utilizing concentrated rIL-18 
preparations and rpIL-12 co-stimulation.  High variance in measurements was the result of a 
large variability in the response to stimulation between pigs.  PBMC samples from different 
pigs responded similarly to each treatment group, but displayed a high degree of variability 
in the level of sensitivity to stimulation between pigs.  To control for the variability between 
test subjects, the respective negative control was subtracted from each sample (Ex. [Pig1-24h 
Ad5+mutIL-18K:F2] – [Pig1-24h Ad5B]) (Fig. 2.12).  Figure 2.12 shows both mutIL-18 
treatment groups resulted in the generation of appreciably elevated levels of IFN- protein 
expression compared to the negative control group and the wtIL-18 treatment group [Two-
way ANOVA analysis (P<0.05)] (Fig. 2.11 & 2.12).  As noted previously, the AD5+mutIL-
18K:F2 isolate contains a frameshift insertion 13 bp upstream of the stop codon.  The effects 
of the frameshift mutation are unknown but may be the cause of the reduction in biological 
activity compared to the Kozak [E] isolate (Ad5+mutIL-18K:E3).   
The biological activity trials have indicated the response to treatment groups have a 
high degree of animal to animal variability.  A genetic component, health status, or 
unidentified environmental factor may play significant role in response to treatment in the in 
vitro biological activity assay.  Additional trials are needed to determine definitively the 
biological activity of the rIL-18 isolates.  The establishment of protocols to generate rIL-18 
samples of higher concentration would presumably aid in the testing of biological activity.  
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Repeated measures from the same blood sample may be needed to account for inherent 
variability between PBMCs from different subjects.  The removal of viral or cellular products 
while maintaining a high concentration of rIL-18 protein would help ensure accurate 
measurements of biological activity of rIL-18 proteins.   
While the removal of viral and cellular components was attempted by filtration prior 
to protein concentration, compounds between 10kD and 100kD MW remained and were 
concentrated 10-fold.  Furthermore, adenoviral titers of concentrated protein samples were 
between 1.0 X 10
9
 to 5.6 X 10
9
 TCID50/mL.  Adenoviruses are able to infect lymphocytes 
and monocytes (Segerman et al., 2006; van der Veen and Lambriex, 1973).  Even though test 
isolates are replication defective, infection alone may cause up-regulation of some 
immunological pathways.  The adenovirus control group Ad5B was able to illicit some level 
of IFN- protein expression when PBMCs were co-stimulated with rpIL-12 or con A/rpIL-
12.  The induction of IFN- expression by Ad5B is concurrent with a previous study 
(Hartman et al., 2007).  It was reported a similar LacZ expressing adenovirus was able to up-
regulate Jak/STAT, MAPK, TLR, and apoptotic-related pathways as well as induce a MyD88 
mediated IFN- response in vivo (Hartman et al., 2007). 
In vivo, IFN- levels detected in serum and nasal wash samples are below the limits 
of the ELISA assay (~2 pg/mL).  Further research is required to confirm current findings.  
With an estimated molecular weight of 17kD, low molecular weight centrifugal columns 
(10kD) could be utilized to concentrate IFN- samples 4 to 6 fold.  Condensing sample 
volumes 4 to 6 fold would elevate IFN- protein concentrations in the nasal washes to levels 
within the limits of the ELISA.   
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Adenoviruses are well suited for mucosal administration, including oral and 
intranasal routes, able to elicit high IgA antibody titers and effective CD8+ T cell responses 
(Croyle et al., 2008; Phillpotts et al., 2005; Tang et al., 2009; Tucker et al., 2008; Walter et 
al., 2001; Xiang and Ertl, 1999).  Intranasal administration of rIL-18 expressing adenoviruses 
did result in consistent, albeit low, IFN- induced expression following a time dependent 
pattern.  Previous studies expressing IFN-or IL-18 by similar adenoviral vectors in vivo 
also reported steep declines in expressed protein levels on or before day 3 post vaccination 
(Brockmeier et al., 2009; Walter et al., 2001).   
The generation of a mutated IL-18 cDNA construct was confirmed by sequencing.  
Utilizing a CMV promoter and strong Kozak initiator sequences resulted in high levels of 
rIL-18 expression by both wtIL-18 and mutIL-18 adenoviral expression vectors.  In vitro, 
biological activity of mutIL-18 isolates were shown to be appreciably higher than the 
negative control or wtIL-18 treatment groups.  However, the biological activity of the wtIL-
18 protein was consistently lower than expected.  Future research may need to focus on 
developing methods to concentrate and purify the rIL-18 protein preparations.  Previous 
literature utilized rIL-18 concentrations ≥100ng/mL to display biological activity (Liu et al., 
2000; Munder et al., 1998; Ushio et al., 1996; Yamamoto et al., 2004).  Generation of high 
concentration rIL-18 preparations would allow the evaluation of biological activity at 
standardized dilutions, correlating IFN- induction to rIL-18 concentrations in a dose 
dependent manner.  While current findings need further evaluation, results indicate an 
increase in biological activity by the mutated IL-18 over the wild type porcine IL-18 as 
measured in vitro.  In vivo the low levels of IFN- within the nasal swabs did not suggest an 
elevation in biological activity of mutIL-18 over the wild type form.   
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Abstract 
Current influenza vaccines effectively elicit protective immunity against antigenically 
similar strains of the same subtype, but not against the broader class of subtypes currently 
circulating.  Broad cross-reactive immunity (heterosubtypic immunity) has been attributed to 
both humoral and cell mediated immune responses.  However, at young ages, animals exhibit 
dysregulated immune functions, as compared to adults, including reduced expression of 
inflammatory mediators and diminished TH1 T cell response.  Expression of an important 
TH1 pro-inflammatory cytokine, IL-18, is significantly diminished at the mucosal epithelium 
in young piglets.  IL-18 is a critical signaling component for the development of a strong 
CMI response and effective viral clearance during influenza infection.  Here we report the 
characterization of the immunomodulatory effects of recombinant porcine IL-18 expression 
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on the immune response to a modified live virus (MLV) swine influenza vaccine.  Two 
amino acid conversions were introduced to wild type porcine IL-18 to generate a mutated 
analog exhibiting increased biological activity.  Wild type and mutated IL-18 expression 
vectors were generated from a replication defective adenovirus and a modified live influenza 
virus.  Vaccinations were administered as a single dose MLV influenza vaccine by intranasal 
route.  Upon challenge by a heterosubtypic strain, the mutated IL-18 vaccination groups 
exhibited lower viral shedding, lower pulmonary viral titers, slightly reduced macroscopic 
lung lesion scores, and significantly elevated antibody responses.  Flow cytometric analysis 
revealed significant differences in responding T cell populations between vaccination groups 
and expression vectors.  Results indicate the expression vectors along with administration of 
IL-18 can contribute significantly to activate T cell responses.  
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1. Introduction 
Influenza is an important human and animal pathogen typically causing high rates of 
morbidity in a diverse range of avian and mammalian hosts.  In the northern hemisphere, 
influenza infection is characterized by seasonal epidemics occurring annually during the 
winter months.  In mammals, influenza infection manifests as a mild to severe respiratory 
infection transmitted by large droplet aerosols or direct contact.  In 2001, influenza 
associated diseases were ranked the seventh leading cause of death in the human population 
within the United States (Anderson and Smith, 2003).  Worldwide, it is estimated 3 to 5 
million severe cases of influenza infection will develop annually resulting in 250,000 to 
500,000 deaths (WHO, 2003).   
Influenza viruses evolve rapidly due to its segmented genome and error prone 
replicase in response to immunological pressure.  The rapid changes to the major antigenic 
sites of influenza virus requires current vaccines continually be updated.  Current influenza 
vaccines generally elicit protective immune responses to antigenically similar strains of the 
same subtype.  However, antigenically distinct viruses of numerous subtypes currently 
circulate in human and swine populations.  Even with current vaccine strategies, it is 
estimated seasonal influenza costs the US economy between $71-$116 billion annually 
(WHO, 2003).  In the swine industry, influenza related disease was ranked as the second 
leading cause of economic losses for swine producers (Holtkamp et al., 2007).  Broad cross-
reactive immunity against multiple influenza subtypes (heterosubtypic immunity) has been 
noted following infection by live influenza viruses (reviewed in (Tamura et al., 2005).  Due 
to the enhanced protective immune responses to live infection, attenuated modified live virus 
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(MLV) vaccines elicit better CMI responses than inactivated killed vaccines and tend to 
induce stronger heterosubtypic immunity (Liang et al., 1994; Schulman and Kilbourne, 1965; 
Tamura et al., 2005). 
Vaccination against swine influenza virus is often completed at a young age in swine.  
However, the neonatal immune system exhibits a host of dysregulated or insufficient immune 
responses including pro-inflammatory pathways and biased of T cell polarization (Forsthuber 
et al., 1996; Pertmer et al., 2001; Ridge et al., 1996; Sarzotti et al., 1996).  In neonates, T cell 
differentiation often results in a TH2 biased response due to an impaired ability to polarize T 
cells to the TH1 phenotype (Breathnach et al., 2006; Forsthuber et al., 1996; Pertmer et al., 
2001; Sarzotti et al., 1996; Siegrist, 2001; Siegrist et al., 1998; Suen et al., 1998).  Expression 
of IL-18, an important cytokine involved in pro-inflammatory responses and T cell 
polarization towards a TH1 response, is known to be markedly diminished in the respiratory 
mucosal epithelium during the first months of a pig’s life (Muneta et al., 2002). The mucosal 
surface of the porcine respiratory tract is a primary site of infection in young piglets.  IL-18 
knock out studies in mice have demonstrated the need for IL-18 in order to generate 
protective responses against influenza infection (Billaut-Mulot et al., 2000; Denton et al., 
2007; Foss et al., 2001; Liu et al., 2004; Takeda et al., 1998).  In IL-18 deficient (IL-18 
-/-
) 
mice, influenza virus titers reached maximum levels earlier in the course of infection, had 
significantly higher virus titers, significantly reduced IFN-γ induction, and lower activity 
levels of natural killer cell-mediated cytolysis (Billaut-Mulot et al., 2000; Denton et al., 
2007; Dinarello, 1999; Foss et al., 2001; Liu et al., 2004; Takeda et al., 1998).  Additionally, 
IL-18 maturation is inhibited upon influenza infection by the NS1 protein (Egorov et al., 
1998).   
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The NS1 protein is involved in a variety of functions to evade host antiviral 
responses.  NS1 inhibits mRNA nuclear export by binding of the poly(A) tail of mRNAs, 
hinders the polyadenylation of host mRNAs, and prevents pre-mRNA splicing by U6 
spliceosome snRNA binding (Fortes et al., 1994; Nemeroff et al., 1998; Qiu et al., 1995).  
NS1 inhibits type I interferon activation via its carboxyl-terminal domain, preventing 
activation of signaling pathways such as 2’-5’ oligo (A) synthetase/RNase L, PKR, NF-kB, 
and IRF-3 (Geiss et al., 2002; Lu et al., 1995; Mibayashi et al., 2007; Min and Krug, 2006; 
Siren et al., 2006).  Generating various N-terminal mutations to the NS1 protein, Stasakova et 
al. (2005) showed the NS1 protein inhibits the activation of the inflammasome complex 
resulting in a 5-fold reduction of biologically active IL-18 and 10-50 fold reduction in 
biologically active IL-1 (Stasakova et al., 2005).  Inflammasome activation and subsequent 
induction of the ASC/caspase-1-dependent pathway is required for establishment of CD8+ T-
cell responses and B-cell secretion of IgA antibodies at the mucosal surface (Petrilli et al., 
2007; Stasakova et al., 2005), both critically important to mucosal immunity.  NS1 is 
believed to inhibit inflammasome activation by binding ssRNA and dsRNA to reduce 
detection by PRR receptors such as TLR3, TLR7 and RIG-I, although exact mechanisms are 
still being characterized.   
To evaluate the immunomodulatory effect of IL-18 administration in conjunction 
with a one dose modified live swine influenza vaccine, viral vectors were generated to 
express recombinant IL-18 (rIL-18).  Previous work by Kim et al. (2001) on human IL-18 
has shown the mutation of two amino acids involved in IL-18 binding to the inhibitory IL-18 
binding protein (IL-18BP) resulted in extended half-life and a 4-fold increase in biological 
activity (Kim et al., 2001; Kim et al., 2000).  To evaluate if homologous mutations to porcine 
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IL-18 would result in similar findings, a porcine mutIL-18 homolog was generated from wild 
type porcine IL-18.  For use in vaccines, replication-defective adenovirus expression vectors 
delivering either wild type IL-18 (Ad5+wtIL-18) or mutated IL-18 (Ad5+mutIL-18) were co-
administered with a H3N2 triple reassortant modified live swine influenza virus (Garcia-
Sastre et al., 1998; Richt et al., 2006; Solorzano et al., 2005; Vincent et al., 2007) containing 
a 93 amino acid carboxyl-terminal truncation of the NS1 gene [Tx98NS1126 MLV].  To 
generate a single component influenza vaccine which expresses IL-18, the mutIL-18 cDNA 
construct was inserted into the truncated region of the NS1 [126] gene of this virus.  The 
resulting recombinant modified live virus [MLV+mutIL-18] was confirmed to express rIL-18 
using a swine IL-18 ELISA.  Here we report the immunomodulatory properties of rIL-18 in 
vivo when co-administered in one of two replication defective adenovirus vectors 
(MLV+Ad5wtIL-18 or MLV+Ad5mutIL-18) or when given as a single virus construct in the 
form of the MLV+mutIL-18.  Efficacy of IL-18 as an adjuvant to influenza vaccination was 
evaluated in a heterosubtypic swine influenza virus challenge (H1N1 IA04) model in young 
pigs. 
 
2. Materials and Methods 
2.1 Mutagenesis of porcine IL-18 
Dual point mutations were introduced into a porcine wild type IL-18 encoding cDNA 
construct by PCR primer site-directed mutagenesis.  Two sets of PCR primers were designed 
to individually introduce amino acid conversions at positions 41 (E to A) and 88 (K to A).  
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Mutations and full-length sequence fidelity was confirmed by sequencing (Fig. 2.1).  The 
mutIL-18 plasmid was previously generated by Ma et al. (unpublished data).  
 
2.2 Generation of Tx98NS1126 MLV containing mutIL-18 
Live influenza A virus Tx98NS1Δ126 (MLV) (A/Swine/Texas/4199-2/98) was 
generated by reverse genetics as previously described (Solorzano et al., 2005).  All genomic 
segments of the Tx98NS1Δ126+mutIL-18 recombinant influenza virus were unaltered except 
for the NS1Δ126 genetic segment.  The NS1 gene of Tx98NS1Δ126+mutIL-18 was 
generated by reverse genetics incorporating the pro form of mutIL-18 to the 3’ end of the 
NS1Δ126 gene fragment.  The Tx98NS1Δ126+mutIL-18 (MLV+mutIL-18) recombinant 
virus was recovered by the same reverse genetic techniques as the MLV (Solorzano et al., 
2005).   
 
2.3 In vitro expression of rIL-18 
Expression of rIL-18 by MLV+mutIL-18 was confirmed by swine IL-18 enzyme-
linked immunosorbent assay (ELISA) (Invitrogen, Grand Island, NY) and by 
immunofluorescence assay (IFA).  Characterization of expression by adenoviral vectors 
containing rIL-18 was described previously (Kappes et al., 2009). 
Immunofluorescence assay (IFA):  Microtiter plates were seeded with low passage 
MDCK cells and allowed to grow to confluency.  Cell sheets were inoculated with MLV, 
MLV+mutIL-18, or with plain media as a cell culture control in triplicate.  At 24 hour post 
inoculation (p.i.), cell sheets were washed with sterile phosphate buffered saline (PBS) three 
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times prior to treatment with 10 g/mL goat anti-porcine IL-18 and incubated for one hour.  
Wells were again washed with sterile PBS three times, treated with fluorescein 
isothiocyanate (FITC)-labeled donkey anti-goat antibody, and incubated for 1 hour.  Cell 
sheets were washed a final time with sterile PBS prior to reading. 
Swine IL-18 ELISA:  In four independent trials, 90-100% confluent low passage 
MDCK cells were inoculated at an approximate multiplicity of infection (MOI) of 25 and 
incubated at 37
°
C, 5% CO2 for the duration of each time point.  Samples were collected every 
12 hours for two days.  Just prior to use, samples were freeze/thawed (F/T) a total of 3 times 
to maximize the release of intracellular rIL-18.  Measurement of rIL-18 protein was 
performed in duplicate using a swine IL-18 ELISA (Invitrogen, Grand Island, NY) per 
manufacturer’s instructions. 
  
2.4 In vitro assessment of rIL-18 biological activity 
Biological activity of rIL-18 expressed protein was assessed by using porcine 
peripheral blood mononuclear cell (PBMC) responsiveness to rIL-18 treatments, as measured 
by secretion of IFN-- into PBMC culture supernatants.  Porcine PBMCs were isolated by 
Vacutainer CPT
TM 
tubes or by density gradient separation over a percoll density gradient 
(1.084 sp gr) from whole blood collected with 2X acid citrate dextrose (ACD) as 
anticoagulant (Ulmer et al., 1984).  Multiple trials were performed utilizing selected co-
stimulatory agents and rIL-18 preparation methods.  rIL-18 stimulated PBMCs were cultured 
with RPMI 1640 media and incubated at 39
°
C, 5% CO2 for the duration of each time point.  
Samples were freeze/thaw a total of three times to release intracellular IFN--.  
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Measurements of IFN-- in cell lysate supernatants was performed in duplicate using a swine 
IFN-- ELISA per manufacturer’s instructions (Invitrogen, Grand Island, NY).   
 
2.5 Hemagglutination Inhibition Assay 
Sera samples were prepared by heat inactivation of complement by incubation at 56
°
C 
for 30 minutes followed by incubation at room temperature with a 20% kaolin suspension for 
30 minutes to remove nonspecific inhibitors.  Finally, sera were incubated with a 0.5% (v/v) 
turkey red blood cells (RBC) solution for 20 min at room temperature.  MDCK propagated 
Tx98 and IA04 influenza A stocks were diluted to an HA=8 for use as standard antigen in HI 
tests.  Each treated serum sample was transferred in triplicate as a 1:10 dilution to a 96-well 
microtiter plate and 2-fold serial dilutions were performed.  Standard HI tests were 
performed for each sample. 
 
2.6 Virus titration 
Bronchoalveolar lavage fluid (BALF), nasal swab samples, and influenza inoculum 
samples were titrated by TCID50 as described by Reed and Muench (Muench, 1938) on 
MDCK cells grown in 96-well plates.  Adenovirus inocula were titrated as described in 
(AdEASY™ vector manual, v1.4 Q BIOgene, Carlsbad, CA) by TCID50.  In short, AD-HEK-
293 cells were plated in 96-well plates and allowed to adhere for 1 hour.  Ten fold serial 
dilutions of each adenovirus sample from 10
-1
 to 10
-11 
per 100 μL were prepared and plated in 
replicates of eight.  Plates were incubated at 37
°
C and 5% CO
2 
for 12 days.  On day 12, plates 
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were scored for highest dilution exhibiting CPE in each row and the TCID50 calculated by the 
formula:  
TCID50/1 mL =10
1+d(s-0.5) 
* 10, where d=Log10(dilution), s= sum of ratios 
 
2.7 rIL-18/influenza MLV Animal Study outline  
 Forty-eight three week old pigs were treated with ceftiofur crystalline antibiotic 
(EXCEDE™, Pharmacia) per manufacturer’s recommend dose and randomly separated into 
six groups of eight to be housed for one week prior to primary inoculation.  All pigs were 
confirmed seronegative for SIV by hemagglutination inhibition assays to H1N1 and H3N2 
antigen and free from detectable influenza infection by virus isolation from nasal swabs on 
day 0 post vaccination.  At day 0 post vaccination, adenovirus and influenza inocula were 
prepared by dilution in sterile PBS just prior to use.  Inocula were administered or co-
administered intranasally by slowly dripping 2 mL of each inoculum into the nasal cavity of 
each pig as specified in table 3.1.   
Table 3.1  Swine influenza MLV vaccine animal study (rIL-18/MLV): group outline 
Group N Description Name Challenge
1 8   Adeno 5 w/ mutSwIL-18 Insertion Ad5mutIL-18 IA04
2 8   Tx98NS1Δ126 + Adeno 5 w/ wtSwIL-18 Insertion MLV+Ad5wtIL-18 IA04
3 8   Tx98NS1Δ126 + Adeno 5 w/ mutSwIL-18 Insertion MLV+Ad5mutIL-18 IA04
4 8   Tx98NS1Δ126 w/ mutSwIL-18 insertion MLV+mIL-18 IA04
5 8   Tx98NS1Δ126 MLV IA04
6 8   Wild type Tx98 wtTx98 IA04
Vaccine Treatment Group
 
Back titration of adenovirus and influenza inocula yielded approximately 1 X 10
9
 
TCID50/mL and 1X10
6.5 
TCID50/mL respectfully.  At day 65 post vaccination, all subjects 
were challenged with a heterologous H1N1 wild-type influenza A strain IA04 
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(A/Swine/Iowa/00239/2004) by intranasal inoculation at a dose of 1X10
6.83 
TCID50/mL.  Pigs 
were observed for clinical manifestation of disease for 5 days after challenge (dpc).  Rectal 
temperatures were recorded from day -2 to +5 dpc.  Nasal swabs were obtained for 0, 2, 4, 6, 
65, 68, 70 dpv and serum samples collected on 0, 2, 4, 6, 14, 21, 28, 49, 56, 65, 70 dpv.  
PBMCs were collected using Vacutainer CPT™ tubes containing sodium citrate (BD 
Diagnostics, Franklin Lakes, NJ) on days 14, 28, 49, 56, and 70 dpv.  Virus isolation and 
virus titration assays was performed on nasal swabs for all days collected.  Hemagglutination 
inhibition assays to H3N2 antigen were performed for all days serum was collected and to 
H1N1 antigen for 0, 65 and 70 dpv.  Pigs were euthanized on day 70 post vaccination (5 days 
post challenge) and necropsy performed.  Bronchoalveolar lavage fluid (BALF) (50 mL 
MEM) was collected for virus titration as described in Vincent et al. 2007.  Samples of lung 
tissue, trachea and the tracheobronchial lymph node were fixed in 4% buffered formalin for 
histopathological evaluation. The presence of macroscopic lung lesions for all seven lung 
lobes was examined and scored.   
 
2.8 Cells 
MDCK cells were cultured in Minimal essential medium (MEM) supplemented with 
5% heat inactivated fetal bovine serum, 100 units of penicillin, 100 µg of streptomycin , and 
0.25/mL µg of amphotericin B, 1X L-Glutamine, 1X MEM Vitamins (Gibco, Grand Island, 
NY) and 0.25 mg/L gentamicin sulfate for maintenance.  MDCK cells were transferred to 
influenza infection media containing Minimal essential medium (MEM) supplemented with 
4% bovine serum albumin Fraction V, supplemented with antibiotics and nutrients as stated 
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above, for propagation of influenza virus and in vitro influenza assays.  TPCK [L-
(tosylamido-2-phenyl) ethyl chloromethyl ketone] – Trypsin was added at a 1:1000 dilution 
to influenza infection media just prior to use to cleave the HA viral glycoprotein and 
facilitate viral entry into MDCK cells. 
AD-HEK-293 cells were cultured in Dulbecco's Modified Eagles Medium (DMEM) 
high glucose 1X with 4.5 g/L D-glucose, L-Glutamine, and 110 mg/L sodium pyruvate, 
supplemented with 5% heat inactivated fetal bovine serum, and antibiotics plus antimycotics 
as described above for maintenance of cell line.  For use in adenoviral assays, heat 
inactivated fetal bovine serum was reduced to 2% (v/v), all else held constant.   
Peripheral blood mononuclear cells used for in vitro assessment of IL-18 biological 
activity and in ex vivo flow cytometry assays were obtained by venous puncture and cultured 
in RPMI 1640 media containing L-glutamine and 25mM HEPES, supplemented with 10% 
fetal bovine serum, and antibiotics plus antimycotics as described above. 
 
2.9 Virus 
Influenza A viruses wtTx98 H3N2 (wtTx98) (A/Swine/Texas/4199-2/98), 
Tx98NS1Δ126 (MLV) (A/Swine/Texas/4199-2/98), Tx98NS1Δ126+mSwIL-18 
(MLV+mutIL-18) (A/Swine/Texas/4199-2/98) and wtIA04 H1N1 
(A/swine/Iowa/00239/2004) were propagated in the allantoic cavity of 7-10 day old 
embryonated chicken eggs.  Allantoic stocks of each virus were diluted in sterile PBS to 1 X 
10
6.5
 TCID50/mL on the day of administration for use as inoculums. 
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Low passage replication-defective adenovirus isolates expressing wtIL-18 
[Ad5+wtIL-18] and mutIL-18 [Ad5mutIL-18] were propagated in specialized AD-HEK-293 
cells genetically altered to support replication.  For use as inoculums, adenovirus isolates 
were purified and concentrated by double CsCl density gradients as described in the 
(AdEasy™ vector manual v1.4 Q BIOgene, Carlsbad, CA).  In short, 40 T150 cell culture 
flasks (Corning, Corning, NY) were inoculated per virus.  Samples were collected when CPE 
had reached 100%.  Media was consolidated and spun at 300 rcf for 10 min to obtain a single 
cell pellet, discarding the supernatant.  Pellets were F/T three times to lyse cells and release 
the virus.  Discontinuous gradients (1.4-1.2 CsCl sp gr) were prepared in 50mL 
ultracentrifuge tubes. Samples were overlaid on top of discontinuous gradient and 
centrifuged at 100,000 rcf for 90 minutes.  Concentrated adenovirus was collected by 
aspiration of the adenoviral band and immediately overlaid on previously prepared 
continuous gradients (1.4-1.2 CsCl sp gr) and spun at 100,000 rcf for 20-24 hours.  Resulting 
concentrated adenoviral isolates were desalted by dialysis in 10 mM Tris (pH 8.0), 2 mM 
MgCl2, 4% sucrose buffer.  Purified adenoviruses were titered by tissue culture infectious 
dose 50% (TCID50/mL) as described in the AdEasy™ vector system manual.  Adenoviral 
inoculums were diluted to 1.0 X 10
9
 TCID50/mL in sterile PBS shortly before administration.   
Influenza A viruses wtTx98 H3N2 (A/Swine/Texas/4199-2/98), Tx98NS1Δ126 
(MLV) (A/Swine/Texas/4199-2/98), and wtIA04 H1N1 (A/swine/Iowa/00239/2004) were 
propagated in MDCK cells with influenza infection media for use in CMI flow cytometry 
assays. An aliquot of each virus was UV inactivated by 840 mJoules over the course of 270 
seconds in three successive 90-second intervals, approximately 2-3 seconds between 
intervals.  Both live and UV-inactivated viruses were aliquoted and stored at -80
°
C until use.   
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2.10 Cell Mediated Immunity (CMI) assay 
Influenza A viruses wtTx98, MLV, and wtIA04 viruses were prepared as previously 
described and diluted to 3 X 10
6
 TCID50/ml in RPMI++ (RPMI 1640 (Gibco marketed by 
Invitrogen, Grand Island, NY) with 15% fetal bovine serum (Atlanta biologicals, Norcross, 
GA) and antibiotics plus antimycotics as described above.  
Peripheral blood mononuclear cells were obtained as previously described on days 
28, 49, 56, 70 dpv.  Vacutainer CPT tubes were centrifuged at 1500xg for 30 minutes at room 
temperature (~25
o
C) within 2 hours following blood collection.  Buffy coats were collected 
into 15 mL conical centrifuge tubes (Falcon, BD Labware, Franklin Lakes, NJ).  PBS was 
added to a final volume of 10 mL and samples were centrifuged at 300 rcf for 10 minutes.  
Discarding the supernatants, the wash step was repeated once.  Each PBMC pellet was 
resuspended with 2 mL RPMI++ and mixed well.  The cell suspensions were counted and 
10
7
 PBMC were diluted with RPMI++ to a final volume of 2 mL (5x10
6
 cells/ml final 
concentration). 
Two hundred l of each PBMC suspension with ~5 X 106 cells/mL were added to 
each of 6 wells of a 96-well flat-bottomed tissue culture microtiter plate (Falcon cat, BD 
Labware, Franklin Lakes, NJ).  One well received 50 L RPMI++ as non-antigen stimulated 
control and another well received 50 l Con A solution at 5 g/ml final concentration (as a 
positive control).  Duplicate wells received 50 L of live Tx98wt, Tx98Δ126, and IA04wt 
viruses or UV-inactivated Tx98wt or IA04wt viruses.  The plates were incubated in 5% CO2 
at 37
°
C. 
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Four days after activation, PBMCs were transferred to round-bottomed tissue culture 
microtiter plates (Falcon cat, BD Labware, Franklin Lakes, NJ).  Brefeldin A (50 l) (BD 
Biosciences Pharmingen, San Diego, CA) was added to the samples at the concentration 
recommended by the manufacturer.  The plates were incubated for an additional 4 hours.  All 
antibodies used in the staining were previously titrated for their optimum concentrations in 
the same PBMC setting (data not shown).  All washing steps were performed by 
centrifugation at 400xg for 1 minute.  The PBMC wells were washed once with 100 l 
PBS++ (PBS with 0.5% bovine serum albumin, and 0.1% sodium azide) and the supernatants 
were removed.  The primary antibody mix for surface antigens (50 l) was added to all 
PBMC wells except the secondary antibody control wells and incubated at room temperature 
(RT, 25
°
C) for 15 minutes.  The monoclonal antibody (mAb) mix consisted of mouse anti-
swine CD4 (IgG2b, cat# 74-12-4), mouse anti-swine CD8 (IgG2a, cat# 76-2-11), mouse anti-
swine  TCR-FITC (IgG1, cat# PGBL22A, direct conjugated with fluorescein 
isothiocyanate), mouse anti-swine CD25-PE (IgG1, cat# PGBL25A, direct conjugated with 
phycoerythrin) in PBS++.  All primary mAb were purchased from VMRD, Inc., (Pullman, 
WA).  The direct conjugation of fluorochromes was performed by Chromaprobe (Maryland 
Heights, MO).  The primary antibody mix was removed after incubation and cells were 
washed twice with 100 L PBS++.  The secondary antibody mix for surface antigens (50 L) 
was added to all PBMC wells included the secondary antibody control wells and incubated at 
room temperature for 15 minutes.  The secondary antibody mix consisted of goat anti-mouse 
IgG2b-PE-Cy-7 and goat anti-mouse IgG2a-PE-TR in PBS++.  The secondary antibody mix 
was removed after incubation and the cells were washed three times with 100 L PBS++.  
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For intracellular staining, the PBMC were treated with 100 L BD cytofix-cytoperm solution 
(BD Biosciences Pharmingen, San Diego, CA) at room temp for 30 minutes and washed once 
with BD perm-wash solution (BD Biosciences Pharmingen, San Diego, CA).  The primary 
monoclonal antibody (mAb) mix consisted of rabbit anti-swine IFN- (polyclonal Ab, cat# 
AT-3072) and mouse anti-swine IL-10 biotin (IgG1, cat# AT-3075), both from MBL 
International (Woburn, MA), in BD perm-wash solution (50 L) was added to all wells 
except the secondary antibody control wells and incubated at RT for 15 minutes.  The 
intracellular primary antibody mix was removed after incubation and cells were washed 
twice with 100 L BD perm-wash solution.  Goat anti-rabbit IgG-AF700 (Alexa Fluor 700, 
Invitrogen, Molecular Probes, Eugene, OR, cat #A21038) and streptavidin-APC-Cy7 
(eBioscience, Inc., San Diego, CA, cat #10-4317-82) (50 L) in BD perm-wash solution was 
added to all wells included the secondary antibody control wells and incubated at RT for 15 
minutes.  Cells were washed three times with 100 L BD perm-wash solution.  Ultrapure 
formaldehyde (Polyscience, Warrington, PA) 1% solution in PBS (250 L) was added to all 
wells and the cells were transferred to flow tubes (Falcon cat # 352008, BD Labware, 
Franklin Lakes, NJ) and kept in the dark at 4
°
C until flow cytometric analysis.  The Canto 
(Beckman Coulter, Inc. Fullerton, CA) flow cytometer was used to analyze the samples at the 
Cell and Hybridoma Facilities, Iowa State University.  
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3. Results  
3.1 Generation of mutated porcine IL-18 by site-specific mutagenesis 
Two amino acid conversions were introduced into the wild type porcine IL-18 gene at 
amino acid positions 41 and 88 by site-directed mutagenesis.  Sequencing confirmed desired 
mutations in the porcine mutIL-18 cDNA (Fig. 2.1). 
Figure 3.1  Amino acid alterations between mutIL-18 and wtIL-18 
 
Fig. 3.1.  Sequence analysis of site-directed mutagenesis to porcine IL-18 cDNA at amino acid positions 41 and 88.   
 
3.2 Expression of rIL-18 in vitro  
Figure 3.2-3.5 illustrates IL-18 expression of IL-18 as a result of the MLV+mutIL-18 
mediated IL-18 expression in MDCK cells by immunofluorescence assay (IFA) or enzyme-
linked immunosorbent assay (ELISA); no IL-18 staining was detected in negative controls by 
either method.  Both wtTx98 and MLV inoculation groups failed to produce measureable IL-
18 expression at any time point.  MLV+mutIL-18 treatment group was confirmed by IL-18 
ELISA to express detectable levels of rIL-18 up to ~100 pg/mL. 
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Figure 3.2  Cell culture control (IFA)  
 
Figure 3.3  MLV (IFA) 
Figure 3.4  MLV+mutIL-18 (IFA) 
 
Fig. 3.2-3.4.  MDCK cells were inoculated with either plain media (cell culture control), MLV (influenza virus control), or 
MLV+mutIL-18 virus.  Cells were stained by a goat anti-porcine IL-18 Ab, followed by an FITC labeled secondary anti-
goat Ab.  Green staining indicates presence of IL-18 protein.   
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Figure 3.5  Biological expression of IL-18 by H3N2 influenza isolates 
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Fig. 3.5.  The concentration of rIL-18 protein in MDCK cell culture supernatants of wtTx98, MLV, and MLV+mutIL-18 
isolates was measured at 12-hour time points for 48 hours.  IL-18 protein was measured in duplicate by swine IL-18 ELISA 
from the F/T supernatants of inoculated MDCK cells.  Values are reported as mean ± SE from 4 independent trials. 
 
3.3 Biological Activity 
 In vitro biological activity of wild-type rIL-18 (wtIL-18) and mutated IL-18 (mutIL-
18) were assessed by interferon- (IFN-) induction of rIL-18 treated porcine PBMCs.  A 
variety of parameters such as rIL-18 preparation and concentration, co-stimulatory agents, 
PBMC isolation methods, and PBMC densities was evaluated in an attempt to optimize the 
biological activity assay (Chapter 2).  Further research is required to determine the biological 
activity of wtIL-18 and mutIL-18 proteins.  Results and Biological activity trials are 
described in Chapter 2. 
 
92 
 
0 6 14 22 28 49 56 65 70
0
50
100
150
200
Ad5mutIL-18 MLV+Ad5wtIL-18 MLV+Ad5mutIL-18
MLV+mutIL-18 MLV wtTx98
Days post vaccination
G
ro
u
p
 M
e
a
n
 H
I T
it
e
rs
3.Serologogical responses to vaccination 
Figure 3.6  Hemagglutination inhibition (HI) titers [H3N2] by day post vaccination 
 
 
 
 
 
 
 
 
Fig. 3.6.  Serum samples were collected pre-vaccination (day 0), post vaccination (days 6-65), and post challenge (day 70).  
HI titers were Log2 transformed and group means ± SE calculated.  Values are reported as mean ±SE for each group.   
 
Hemagglutination Inhibition (HI) Titers:  All pigs were serologically negative to 
H3N2 and H1N1 antigens by HI assay on day 0 post vaccination and remained negative to 
H1N1 antigen for the duration of the study. The negative control treatment group 
(Ad5mutIL-18) remained negative to H3N2 & H1N1 throughout the study.  HI titers reached 
their highest levels by days 22 to 28 post vaccination for all groups.  By day 49 post 
vaccination, the MLV+Ad5mutIL-18 sustained a significantly higher antibody response 
compared to the Ad5B control group (Table 3.2).  By day 56 post vaccination, both mutIL-18 
vaccination groups [MLV+AD5mutIL-18 & MLV+mutIL-18] were significantly higher than 
the negative control group.  HI titers for wtTx98 reached significantly higher levels in 
relation to all other treatment groups by day 14 post vaccination and remained significantly 
higher for the remainder of the study.  The antibody response as a result of heterosubtypic 
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challenge was measured at days 3 and 5 post challenge (Fig. 3.6, Table 3.2).  By day 5 post 
challenge, all three treatment groups expressing rIL-18 exhibited significantly higher 
antibody titers as compared to the negative control group, while the MLV vaccination alone 
did not.  The MLV+Ad5mutIL-18 HI titers were also significantly higher than the MLV and 
the negative control groups by day 5 post challenge.   
 
Figure 3.7  Nasal swab samples influenza viral titers [TCID50] post vaccination 
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Fig. 3.7.  Values are reported as the Log10 transformed [TCID50/mL] group means ± SE influenza viral titers of nasal swab 
samples collected on days 2, 4, and 6 post vaccination.  Virus titers on day 0 of the sudsy were below detectable limit of the 
assay for all groups (data not shown).   
 
Viral shedding:  Viral shedding from vaccination and control groups was calculated 
by titration of nasal swab sample collected on days 2, 4, and 6 post vaccination (Fig. 3.8, 
Table3.3) and days 3 and 5 post challenge (Fig. 3.8, Table 3.3).  No influenza virus was 
detected in nasal swabs on day 0 of the study (data not shown).  Mean values of viral 
shedding from the wtTx98 group were approximately 1 X 10
4
 TCID50/mL on days 2 and 4 
post vaccination, recovering to less than 1 X 10
1
 TCID50/mL by day 6.  No influenza virus 
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was detected in the nasal swabs of the negative control group at any time point prior to 
challenge.  MLV vaccination produced low level viral shedding on days 2 and 4 post 
vaccination (≤100.54 TCID50/mL).  A single measureable titer was detected for vaccination 
group MLV+mutIL-18 on day 4 post vaccination [10
0.69
TCID50/mL] and MLV+Ad5wtIL-18 
vaccination group on day 2 post vaccination [10
0.31
 TCID50/mL].  No viral shedding was 
detected at any day prior to challenge for MLV+Ad5mutIL-18.  All vaccination groups were 
negative by day 6 except the wild-type control (wtTx98).   
Figure 3.8  Nasal swab samples influenza viral titers [TCID50] post challenge 
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Fig. 3.8.  Values are reported as the Log10 transformed [TCID50/mL] group means ± SE influenza viral titers of nasal swab 
samples collected on days 3 and 5 post challenge.   
 
The evaluation of viral shedding after challenge was measured on days 3 and 5 post 
challenge (Fig. 3.8, Table 3.3). By day 3 post challenge, all pigs were positive to a mean 
group titer of approximately 1 X 10
3 
TCID50/mL.  Both MLV+Ad5mutIL-18 and wtTx98 
treatment groups exhibited significantly (P<0.05) lower viral shedding than the 
MLV+Ad5wtIL-18 treatment group on day 3 post challenge.  By day 5 post challenge, all 
vaccination groups and the wtTx98 control group were significantly (P<0.05) lower than the 
95 
 
negative control group.  The MLV+Ad5mutIL-18 vaccination group also resulted in 
significantly lower (P<0.05) viral shedding than the MLV vaccination group by 5 days post 
vaccination.   
Figure 3.9  BALF viral titer 
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Fig 3.9 BALF (50mL MEM) was collected at time of necropsy.  Influenza titers [TCID50/mL] from each pig were Log10 
transformed.  Group means ± SE of the Log10 transformed data are reported.  Differences between groups were statistically 
significant [One-way ANOVA (P<0.0001)] 
 
BALF viral titers:  BALF samples were obtained at time of necropsy on day 5 post 
challenge. The negative control group exhibited significantly higher viral titers than all other 
vaccination groups (P<0.0001).  All three rIL-18 expressing treatment groups resulted in 
lower BALF virus loads than the negative control group, the MLV vaccination group or the 
wtTx98 group (Figure 3.9, Table 3.3), although not by a statistically significant margin.   
  
 
9
6
 
Table 3.2  Hemagglutination inhibition (HI) titers [H3N2 antigen] by treatment group 
Treatment Group
Ad5mutIL18 0.0 ±0.00 A 0.0 ±0.00 A 0.0 ±0.00 A 0.0 ±0.00 A 0.0 ±0.00 A 0.0 ±0.00 A 0.0 ±0.00 A 0.0 ±0.00 A 0.0 ±0.00 A
MLV+Ad5wtIL-18 0.0 ±0.00 A 0.0 ±0.00 A 19.4 ±5.19 B 18.1 ±4.80 B 18.1 ±4.00 B 11.3 ±2.27 A B 7.5 ±2.07 A B 9.7 ±2.39 A B 13.8 ±3.20 B C
MLV+Ad5mutIL-18 0.0 ±0.00 A 0.0 ±0.00 A 23.1 ±8.52 B 19.7 ±6.30 B 23.8 ±6.90 B 14.1 ±5.40 B 14.0 ±5.42 B 17.5 ±6.49 B 20.3 ±6.15 C
MLV+mutIL-18 0.0 ±0.00 A 0.0 ±0.00 A 27.8 ±8.15 B 18.8 ±6.40 B 23.3 ±5.90 B 12.5 ±4.14 A B 16.0 ±3.97 B 15.0 ±3.74 B 14.4 ±3.87 B C
MLV 0.0 ±0.00 A 0.0 ±0.00 A 19.4 ±6.47 B 15.9 ±5.60 B 19.1 ±6.10 B 9.1 ±3.56 A B 8.8 ±2.81 A B 12.8 ±3.11 B 9.7 ±2.27 A B
wtTx98 0.0 ±0.00 A 3.4 ±1.72 A 105.6 ±39.1 C 131.4 ±69.00 C 117.0 ±40.00 C 83.1 ±37.60 82.0 ±40.52 101.9 ±31.35 70.6 ±22.73
1 Values are reported as group mean ± SE of HI titers.  Mean results labeled as zero were below the detectable limit of  the assay. Differences between groups were significant  [Two-Way ANOVA (P < 0.001)].   
Post Challenge
Hemagglutination Inhibition (HI) titers to H3N2 antigen  1
Post Vaccination
0 +6 +14 +22 +28 +49 +56 0 +5
 
Table 3.3  Quantitation of viral shedding and pulmonary viral titers [TCID50/mL] 
+2 +4 +6 +3 +5
Ad5mutIL18 0.00±0.00 A (0/8) 0.00±0.00 A  (0/8) 0.00±0.00 A  (0/8) 2.87±0.16 A B (8/8) 3.37±0.13 (8/8) 5.29±0.20  (8/8)
MLV+Ad5wtIL-18 0.31±0.21 A (1/8) 0.00±0.00 A  (0/8) 0.00±0.00 A  (0/8) 3.33±0.17 B (8/8) 1.31±0.21 A B (7/8) 0.77±0.38 A  (3/8)
MLV+Ad5mutIL-18 0.00±0.00 A (0/8) 0.00±0.00 A  (0/8) 0.00±0.00 A  (0/8) 2.79±0.22 A (8/8) 1.02±0.22 B C (7/8) 0.62±0.41 A  (2/8)
MLV+mutIL-18 0.00±0.00 A (0/8) 0.69±0.33 B  (3/8) 0.00±0.00 A  (0/8) 2.91±0.19 A B (8/8) 1.54±0.38 A B (6/8) 0.62±0.41 A  (2/8)
MLV 0.54±0.36 A (2/8) 0.23±0.23 A B  (1/8) 0.00±0.00 A  (0/8) 2.96±0.17 A B (8/8) 1.62±0.21 A (8/8) 1.66±0.71 A  (4/8)
wtTx98 3.95±0.33 (8/8) 3.96±0.29  (8/8) 0.62±0.43 B  (2/8) 2.75±0.08 A (8/8) 0.29±0.20 C (2/8) 1.08±0.41 A  (4/8)
BALF and nasal swab viral titers:  Group mean titer viral shedding [TCID50/mL] 1
Nasal Swab2
Treatment Group Days post Vaccination Day post Challenge Day post Challenge
Bronchoalveolar lung lavage3
1  Values are reported as means ± SE of Log10 transformed TCID50 influenza viral titers.   2  Mean results labeled as zero were below the detectable limit of the assay.    Significance between 
group means by Two-Way ANOVA analysis is significant (P<0.0001).  Treatment groups not connected by the same letter are significantly different from each other (P<0.05) by multivariate
Heterogeneous Compound Symmetry residual analysis   3  Significance is reported between group means by One-Way ANOVA analysis (P<0.0001).   Treatment groups not connected by
 the same letter are significantly different from each other (P<0.05) by Tukey HSD Multiple Comparison test 
+5
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Figure 3.10  Mean rectal temperatures 
(
°
C) of adenovirus vaccination groups 
post challenge 
 
Figure 3.11  Mean rectal temperatures 
(
°
C) of non-adenovirus vaccination 
groups post challenge 
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Fig. 3.10-3.11.  Rectal temperatures were recorded from days 0 to 5 post challenge.  Values are reported as group means ± 
SE.  Differences between groups were statistically significant [Two-way ANOVA analysis (P<0.05)] 
 
Febrile response to heterosubtypic challenge:  Rectal temperatures were recorded 
between days 0 to 5 post challenge (Fig. 3.10-3.11, Table 3.4).  A significant difference 
between groups is reported (p<0.05) by Two-way ANOVA analysis.  As noted in table 3.4, 
the MLV+mutIL-18 vaccination group had significantly lower mean rectal temperatures on 
day 3 post challenge compared to the negative control group.   
Table 3.4  Rectal temperatures days 0-5 post challenge by group 
38.5 ±0.3 A 38.5 ±0.2 A 38.6 ±0.2 A 39.2 ±0.1 A 38.7 ±0.1 A 38.6 ±0.2 A
38.9 ±0.1 A 39.2 ±0.2 A 39.1 ±0.1 A 38.9 ±0.2 A B 38.7 ±0.2 A 38.0 ±0.3 A
38.7 ±0.1 A 38.3 ±0.1 A 38.8 ±0.2 A 38.5 ±0.3 A B 38.5 ±0.1 A 38.1 ±0.2 A
38.6 ±0.2 A 38.5 ±0.2 A 38.4 ±0.2 A 38.1 ±0.2 B 38.4 ±0.2 A 38.1 ±0.2 A
38.8 ±0.2 A 39.1 ±0.1 A 38.9 ±0.2 A 38.8 ±0.1 A B 38.1 ±0.1 A 38.6 ±0.1 A
38.8 ±0.1 A 38.5 ±0.2 A 38.9 ±0.2 A 38.7 ±0.1 A B 38.4 ±0.2 A 38.2 ±0.1 A
as calculated by residule compound symmetry family wise comparison
1     Values are reported as group means ± SE (N=8).  Differences between group means were statistically significant 
[Two-Way ANOVA (p<0.01)].  Levels not connected by the same letter are  significantly different from each other (P<0.05) 
Ad5mSwIL18
Txdel126+Ad5wtSwIL18
Txdel126+Ad5mSwIL18
Txdel126 w/ mSwIL18
Tx98del126
Tx98 wt
Group Mean Rectal Temperature (days post challenge)
Days post Challenge1
Treatment Group 0 1 2 3 4 5
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Figure 3.12  MLV+Ad5mutIL-18 
[Ventral] 
 
 
Figure 3.13  MLV+Ad5mutIL-18 
[Dorsal] 
 
 
 
Figure 3.14  wtTx98 vaccination control 
[Ventral] 
 
 
Figure 3.15  wtTx98 vaccination control 
[Dorsal] 
 
Fig. 3.12-3.15.  Lungs were removed in toto and macroscopic lung lesions of each individual lobe were scored as a percent 
surface area of pneumonic lung lesions.  As seen in figures 3.14 & 3.15, macroscopic lung lesions are plum colored 
consolidated areas noted on all lobes of the lung.   
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Figure 3.16  Macroscopic lung lesion score [% surface area pneumonic lesions]  
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Fig. 3.16.  Macroscopic lung lesions were scored as a percent surface area exhibiting pneumonic lung lesions on each lobe.  
Total weighted averages of the surface area were calculated for each lung.  Values are reported as group means ± SE.  
Differences between groups were not statistically significant (P>0.05) as calculated by One-way ANOVA analysis.   
 
Table 3.5  Macroscopic lung lesion 
scores by treatment group 
Macroscopic lung Lesions:  At time of 
necropsy, each lung was removed in toto and each 
lobe of the lung was scored as a percent surface area 
of the lung afflicted with pneumonic lesions.  
Typical lesions resulting from SIV infection are 
characterized by consolidated, plum-colored areas 
on the lung lobes, as seen in Figures 3.14 & 3.15.  A 
weighted average of the percent total surface area for each lung was calculated (Fig. 3.16, 
Table 3.5).   
Mean SE
5.6 ±0.7
9.6 ±0.8
7.7 ±1.0
7.4 ±1.5
9.5 ±1.4
12.1 ±2.6
MLV+mutIL-18
MLV
wtTx98
1   Means ± SE are  reported.  Differences between 
groups are not statistically different [One-way 
ANOVA (p>0.05)] 
MLV+Ad5mutIL-18
Macroscopic lung lesion scores1
[% surface area weighted average]
Treatment Group
Ad5mutIL-18
MLV+Ad5wtIL-18
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Cell mediated immunity (CMI) flow cytometry assay:  PBMC samples were 
collected at 4, 7, 8, and 10 weeks post vaccination via Vacutainer CPT™ tubes for use in the 
CMI flow assay (Fig. 3.17-3.22).  PBMCs were diluted in 96-well cell culture plates to a 
final concentration of 1 X 10 
6
 PBMC/well and stimulated ex vivo with either live wtTx98, 
wtIA04, Tx98NS1126 MLV, or UV inactivated wtTx98 or wtIA04 viruses 96 hours after 
antigen addition, cells were fixed and fluorescently labeled by mAb for cell surface markers 
[CD4, CD8, , and CD25] as well as IFN-and IL-10 to evaluate responses to ex vivo 
stimulation by homologous and heterosubtypic influenza viruses.  CD25, the IL-2 receptor  
chain, was used as an activation marker.  IFN- and IL-10, TH1 and TH2 type cytokines 
respectively, were chosen to evaluate the phenotypic cytokine expression of the various T-
cell populations at each respective time point.  Data from weeks 7 and 8 were averaged to 
obtain an estimate of T cell response.  Expression indexes (EI) were calculated for each 
treatment group, at each time point, for each simulating antigen.  EIs are a dividend between 
the product of the percent positive cells and the respective mean florescence intensity of 
stimulated cells divided by the product of the percent positive cells and the respective mean 
florescence intensity of the unstimulated cells.   
Response to H3N2 antigen:  CD25 a T cell activation marker for flow cytometric 
analysis.  CD4+, CD8+, and non T cell populations failed to up-regulate CD25+ expression 
above baseline following antigen stimulation (Fig. 3.21).  Prior to challenge, the wtTx98 
vaccination control group exhibited significantly higher CD25 expression than all other 
vaccination groups in the CD4+CD8+ T cell population.  However, By 1 week post 
challenge, the MLV+mutIL-18 vaccination group exhibited the highest CD25+ expression in 
CD4+CD8+ T cells and was significantly higher than the negative control group (Fig. 3.21).  
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Similarly, by one week post challenge, the MLV+mutIL-18 vaccination group was the 
highest inducer of CD25+ on  T cells and was significantly higher than both the MLV 
vaccination group and the negative control group (Fig. 3.21).   
IFN- expression surprisingly was significantly diminished by all three rIL-18 
vaccination groups in CD8+ T cells by one week post challenge (Fig. 3.18).  IFN- 
expression by the PBMCs from the wtTx98 vaccination control group tended to be higher 
than all other vaccination groups regardless of T cell population or time point.  By one week 
post challenge, the MLV+mutIL-18 group also exhibited significantly higher IFN-
expression in  T cells compared to the negative control group or either of the adeno+IL-
18 vaccination groups [MLV+Ad5wtIL-18 & MLV+Ad5mutIL-18].   
Data from both the H3N2 and H1N1 antigen stimulation sets indicate the expression 
vector itself also contributes significantly to the type of T cell population responding as well 
as the phenotypic response.  As seen in the IL-10 expressing CD4+CD8+ and CD8+ T cell 
subsets one week post challenge [H3N2 antigen stimulation] (Fig. 3.17) and in the CD8+ 
IFN- expressing T cell population 7/8 weeks post vaccination [H1N1 antigen stimulation] 
(Fig. 3.20); all adenoviral groups including the negative control group were significantly 
elevated in comparison to non-adenovirus groups regardless of MLV co-administration or 
wtIL-18 verses mutIL-18 expression.   
Response to H1N1 antigen:  CD25+ expression was not appreciably elevated above 
the baseline by any group above or at any time point in response to stimulation by H1N1 
antigen.  By 7/8 weeks post vaccination, all three adenoviral groups (Ad5mutIL-18, 
MLV+Ad5wtIL-18, MLV+Ad5mutIL-18) exhibited significantly higher IFN- expression by 
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CD8+ T cells, compared to non-adenovirus groups (Fig. 3.20).  Vaccination with 
MLV+Ad5mutIL-18 resulted in significantly higher IL-10 expression in CD4+ SP, 
CD4+CD8+ DP, CD8+, and  T cell populations in comparison to all other vaccination 
groups except for MLV+Ad5wtIL-18 group by one week post challenge in response to live 
H1N1 antigen stimulation.  Additionally, the MLV+Ad5wtIL-18 vaccination group, along 
with MLV+Ad5mutIL-18, induced significantly higher IL-10 expression in CD4+ and 
CD4+CD8+ DP T cell populations compared to all other vaccination groups by one week 
post challenge when stimulated with live H1N1 antigen.   
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Figure 3.17  CMI assay: IL-10 EI [Live wtTx98 H3N2] by group 
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Figure 3.18  CMI assay: IFN- EI [Live wtTx98 H3N2] by group 
 
 
 105 
 
Figure 3.19  CMI assay: IL-10 EI [Live wtIA04 H1N1] by group 
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Figure 3.20  CMI assay: IFN- EI [Live wtIA04 H1N1] by group 
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Figure 3.21  CMI assay: CD25 EI [Live wtTx98 H3N2] by group 
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Figure 3.22  CMI assay: CD25 EI [Live wtIA04 H1N1] by group 
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The CD25 CMI flow cytometric analysis for the 10
th
 week post vaccination (~1 week 
post challenge) grouped by antigen is displayed in Figure 3.23.  The CD4+CD8+ DP T cell 
and the  T cell populations are the major activated T cell groups responding to H3N2 
antigen by up-regulating the CD25+ EI for all treatment groups other than the negative 
control group.  DP T cells and  T cell T cells expressing CD25 only responded to 
significant levels when stimulation by the Tx98 antigens (live, UV killed, or the MLV 
antigen stimulation groups).  Reactions to H1N1 IA04 viruses (either live or UV inactivated) 
were not detected for CD25 positive cells.   
 [Figure 3.24] Stimulation with Tx98 wt antigen (live and UV inactivated) and 
wtIA04 antigen induced IL-10 expression to significant levels in multiple vaccination groups.  
Both CD4+ and CD4+CD8+ T cell populations expressing IL-10 responded in highest 
intensities to the heterosubtypic IA04 challenge virus for both MLV+Ad5wtIL-18 and 
MLV+Ad5mutIL-18 vaccination groups.  IL-10 expressing cells in CD4+, CD4+CD8+, 
CD8+ T cell populations and all T cell subsets stimulated with any Tx98wt antigen (Live, 
UV inactivated, or MLV) were below baseline for the MLV+mutIL-18 group.  The wtTx98 
vaccination control group displayed significantly high levels of IL-10 production by  T 
cells responding to Tx98 antigen stimulation (either live, UV inactivated, or MLV).   
 [Figure 3.25] CD4+ and CD4+CD8+ T cell populations from the MLV+Ad5wtIL-18 
and MLV+Ad5mutIL-18 vaccination groups resulted in modest increase in IFN- EI in 
response to Tx98 (live or UV inactivated) and live IA04 viruses.   and non-T cells from 
the MLV+mutIL-18 treatment group displayed elevated levels of IFN- expression in 
response to stimulation ex vivo by Tx98 virus (live, UV inactivated, MLV).  Every T cell 
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population except the CD8+ T cell pool of the wtTx98 treatment group resulted in elevated 
IFN- EI levels in response to stimulation with Tx98 antigen (live, UV inactivated, MLV). 
Figure 3.23  CMI Assay: CD25 EI by antigen: 10 weeks post vaccination 
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Figure 3.24  CMI Assay: IL-10 EI by antigen: 10 weeks post vaccination 
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Figure 3.25  CMI Assay: IFN- EI by antigen: 10 weeks post vaccination  
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4. Discussion 
Current swine influenza vaccines effectively induce immunological protection against 
antigenically similar strains of the same subtype, but not from other subtypes of circulating 
influenza viruses.  Due to their segmented genome and error prone replicase, influenza 
viruses rapidly mutate to evade the narrow protective immunity conveyed by current swine 
influenza vaccines.  Broad cross-reactive immunity or heterosubtypic immunity can be 
elicited following infection by live influenza viruses (Quan et al., 2007), although the exact 
underlying mechanisms are not well understood.  It is believed the induction of 
heterosubtypic immunity involves cell mediated immunity targeting conserved internal 
influenza proteins and cross reactive S-IgA and IgG antibodies neutralizing virus and 
generating virus-antibody complexes (Benton et al., 2001; Graham and Braciale, 1997; Liang 
et al., 1994; Moran et al., 1999; Nguyen et al., 2000; Schulman and Kilbourne, 1965; Tamura 
et al., 2005; Topham et al., 1996).  Due to the enhanced protective immune responses to live 
infection, attenuated modified live virus (MLV) vaccines elicit better CMI responses than 
current inactivated killed vaccines and tend to induce stronger heterosubtypic immunity 
(Liang et al., 1994; Schulman and Kilbourne, 1965; Tamura et al., 2005).  A modified live 
influenza virus (Tx98NS1126) has been previously described as an effective swine 
influenza vaccine against homologous and homosubtypic challenge (Richt et al., 2006).  
Intranasal administration of the MLV was proven to be an effective route of vaccination as a 
single dose, but was shown to convey little protection to heterosubtypic challenge (Vincent et 
al., 2007).   
Vaccination against swine influenza is often administered at a young age in swine.  In 
young animals, formulation of phenotypic TH1 immune responses are impaired due to their 
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immunologically naïve state (Breathnach et al., 2006; Forsthuber et al., 1996; Pertmer et al., 
2001; Ridge et al., 1996; Sarzotti et al., 1996; Siegrist, 2001; Siegrist et al., 1998; Suen et al., 
1998).  Vaccination at this stage of life may result in a biased TH2 immune response that is 
not fully protective.  Studies have shown in some cases that therapeutic treatments, such as 
cytokine administration, are able to restore correct immune function (Pertmer et al., 2001; 
Ridge et al., 1996; Siegrist, 2001) or enhance protective immunity (Zuckermann et al., 1998).  
IL-18 is an important cytokine involved in the development of strong CMI response and in 
the clearance of influenza virus during infection (Akira, 2000; Biet et al., 2002; Billaut-Mulot 
et al., 2000; Denton et al., 2007; Dinarello, 1999; Pirhonen et al., 1999).  In the presence of 
IL-12, IL-18 induces a strong TH1 immune response, primarily by stimulating IFN- 
production and by activating CTL, NK cells, and APCs (Akira, 2000; Biet et al., 2002; Dai et 
al., 2006; Fortin et al., 2009; Kojima et al., 1998; Pirhonen et al., 1999; Yoshimoto et al., 
1997; Zhang et al., 1997).  IL-18 expression is known to be significantly diminished in 
mucosal epithelial cells of young pigs for months after birth (Muneta et al., 2002).  However, 
administration of exogenous IL-18 to the mucosal epithelial cells of young pigs restored IFN-
 induction even when Con A stimulation was unable to (Muneta et al., 2002).  We theorized 
the administration of IL-18 via viral expression vectors in conjunction with the previously 
described swine influenza MLV vaccine (Tx98NS1126) would enhance protective 
immunity against influenza infection.  By the addition of IL-18, it was believed the 
immunomodulatory effect would result in a stronger cell mediated immune response eliciting 
enhanced heterosubtypic infection in young swine.   
In response to vaccination, the MLV+Ad5mutIL-18 vaccination group resulted in 
enhanced protection from heterosubtypic immunity.  As seen in Table 3.2, the 
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MLV+Ad5mutIL-18 vaccination group maintained antibody titers significantly higher than 
the negative control out to day 56 post vaccination.  By 5 days post challenge, the 
MLV+Ad5mutIL-18 vaccination group exhibited elevated antibody titers significantly higher 
than both the MLV and negative control groups (Fig. 3.6 & Table 3.2).  Additionally, 
MLV+mutIL-18 was the only vaccination group not to shed influenza virus post vaccination 
(Fig. 3.7).  By day 3 post challenge, viral shedding from the mutIL-18 vaccination groups 
[MLV+mutIL-18 & MLV+Ad5mutIL-18] were significantly lower than the MLV+Ad5wtIL-
18 vaccination group.  By day 5 post challenge, the MLV+Ad5mutIL-18 vaccination group 
resulted in significantly lower viral shedding compared to the MLV vaccination group and 
negative control group (Fig. 3.8).   
While not statistically significant, the mutIL-18 vaccination groups also resulted in 
lower pulmonary viral titers and reduced macroscopic lung lesion scores compared to the 
MLV vaccination group, the negative control, and the wtTx98 control groups.  It should be 
noted the wtTx98 control group resulted in the highest macroscopic lung lesion scores in 
response to heterosubtypic challenge while the naïve negative control group exhibited the 
lowest pneumonic lung lesion scores.  Post challenge, it would be expected the wtTx98 
vaccination group would have resulted in lowest pneumonic lesions, as wild type influenza 
infection elicits protective immune responses upon recovery from infection, and the 
unvaccinated control group would theoretically have resulted in the highest pneumonic lung 
lesion scores due to an absence to pre-existing immunity.  However, the inverse was 
observed.  Similar findings of enhanced pneumonic lung lesions developing as a 
consequence of heterosubtypic challenge have been previously reported in our lab (Vincent 
et al., 2008).  The mechanism underlying this outcome is unknown.  However, a possible 
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mechanism may be indicated by the correlation of lesion scores and antibody titers.  The 
wtTx98 group induced HI titers 5 to 10 fold greater than the MLV vaccine groups, while the 
negative control group did not result in detectable HI titers.  Enhanced pneumonic lesions 
may result as a consequence of antibody cross-linking.  In some circumstances when high 
quantities of soluble or membrane bound antigens are generated in the presence of reactive 
antibodies (particularly IgG and IgM), substantial cross-linking can form complexes which 
may induce severe inflammation and cell necrosis (Murphy et al., 2008).  The correlation to 
HI antibody titers and lung lesion scores supports this theory.  Enhanced lung lesions may 
also be due to a ‘by-stander’ effect of highly reactive cytotoxic T cells resulting in the death 
of neighboring cells.  Further research will be needed to elucidate the function of enhanced 
lung lesion scores resulting from heterosubtypic challenge.   
To evaluate the phenotypic response of T cell populations in response to MLV 
vaccination and heterosubtypic challenge, six color flow cytometric analysis was used to 
characterize the T cell populations.  By one week post challenge, the MLV+mutIL-18 
vaccination group induced significant increases in CD25+ expression (CD4+CD8+) and IFN-
 expression (g/ T cells, non T cells) in response to stimulation by H3N2 antigen, although 
responses to the H1N1 antigen was marginal.  Conversely, the MLV+Ad5mutIL-18 
vaccination group induced significantly elevated IL-10 expression indexes [CD4+, 
CD4+CD8+, CD8+, and g/ T cells] by one week post challenge in response to H1N1 
antigen (Fig. 3.19).  The MLV+Ad5wtIL-18 vaccination also induced significantly higher IL-
10 levels in CD4+ and CD4+CD8+ T cells in response to H1N1 antigen (Fig. 3.19).  The 
reactivity to H1N1 antigen in the CMI assay by MLV+Ad5wtIL-18 and MLV+Ad5mutIL-18 
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groups indicates T cells from those vaccination groups recognize and respond to viruses of 
other subtypes (H1N1).   
Results also indicate the viral vector significantly contributes to the phenotypic 
response generated by T cells in certain cases.  As seen in the CD4+CD8+ and CD8+ T cell 
subsets one week post vaccination [IL-10 EI, H3N2 antigen stimulation] (Fig. 3.17) and in 
the CD8+ T cell population 7/8 weeks post vaccination [IFN- EI, H1N1 antigen stimulation] 
(Fig. 3.20); a clear demarcation existed between the EIs of adenoviral vaccination groups and 
non-adenoviral vaccination groups regardless of MLV co-administration or form of IL-18 
expressed (wild type or mutated).  While adenoviral vectors are replication-defective, 
infection of cells alone may be enough to up-regulate cellular immune responses.  The fact 
that the negative control vector reacted to an almost identical EI expression level as the 
MLV+adenovirus groups when stimulation with influenza antigen suggests, in those 
instances, the result of adenovirus administration overrode the immune reaction of the 
influenza MLV vaccination itself.  Such results indicate careful consideration may be needed 
when choosing the expression vector in order  to generate the desired immune response upon 
administration.   
Innate activation of  the adaptive arm of the immune system is partly dependent upon 
recognition of pathogens by PRRs such as toll-like receptors, NOD-like receptors (NLRs), 
and C-type lectin receptors (CLRs) expressed on the cell surface or within the cytoplasm to 
detect pathogens by pathogen associated molecular patterns (PAMPs) (Akira et al., 2006).  
Recognition of pathogens by PRRs activate various cellular immune pathways (Petrilli et al., 
2007), and are critical to the induction of proper pro-inflammatory responses.  Upon 
stimulation of pro-inflammatory pathways, inflammasomes are activated.  Inflammasomes 
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are caspase-1 activating multi-protein complexes.  The activation of caspase-1 cleaves IL-1, 
IL-18, and IL-33 pro proteins into their biologically active forms (Petrilli et al., 2007).  
Inflammasome activation and subsequent induction of the ASC/caspase-1-dependent 
pathway is required for the establishment of CD8+ T-cell response and the B-cell secretion of 
IgA antibodies at the mucosal surface (Petrilli et al., 2007; Stasakova et al., 2005).  
The influenza protein NS1 is able to suppress caspase-1 activation, pro-IL-18 
maturation, and caspase-1 dependent apoptosis (Stasakova et al., 2005).  Using a similar NS1 
truncated influenza MLV virus (PR8/NS1-125) Stasakova et al. showed that NS1 was able to 
effectively inhibit IL-1b and IL-18 release from infected human macrophages resulting in 5-
fold reduction biologically active IL-18 release and 10-50 fold reduction in biologically 
active IL-1 release (Egorov et al., 1998; Stasakova et al., 2005).   
While attenuated, the MLV in this study has been previously shown to be an effective 
single dose MLV swine influenza vaccine against homologous and homosubtypic infection 
when administered intranasally (Richt et al., 2006; Vincent et al., 2007).  However, the MLV 
was unable to elicit protective heterosubtypic immunity (Vincent et al., 2007).  As previously 
mentioned, young animals are known to have impaired abilities to formulate TH1 T cell 
responses and young pigs have severely diminished IL-18 expression (Muneta et al., 2002; 
Sarzotti et al., 1996; Siegrist, 2001; Suen et al., 1998).  Additionally, the N-terminal of the 
NS1 protein inhibits release of biologically active IL-18 5-fold (Stasakova et al., 2005).  For 
these reasons, it is theorized the co-administration of IL-18 with swine influenza vaccines 
will result in a superior influenza vaccine.  Based upon previous studies by Kim et al. (2001) 
two amino acid mutations (E41A & K88A) were introduced by PCR primer site directed 
mutagenesis in order to generate an enhanced immunomodulatory agent with extended half-
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life and increased biological activity.  The immunomodulatory effects of IL-18 on the 
immune response of swine influenza MLV vaccination was evaluated in vivo.  Results 
indicated the addition of Ad5mutIL-18 in conjunction with the MLV resulted in superior 
protection to heterosubtypic challenge.   
The vaccination group MLV+Ad5mutIL-18 maintained significantly elevated 
antibody titers post vaccination and resulted in significantly higher mean antibody titers in 
response to heterosubtypic challenge (Fig. 3.6, Table 3.2).  The MLV+Ad5mutIL-18 group 
was the only vaccination group to not shed influenza virus post vaccination (Fig. 3.7, Table 
3.3).  Additionally, vaccination by MLV+Ad5mutIL-18 resulted in significantly lower viral 
shedding post challenge than the MLV vaccination group by day 5 post challenge (Fig. 3.8, 
Table 3.3).   
In the Flow cytometric analysis, the MLV+mutIL-18 effectively up-regulated CD25 
and IFN- expression in CD4+CD8+ and T cell subclasses in response to stimulation by 
H3N2 antigen at one week post challenge.  The MLV+Ad5mutIL-18 vaccination group was 
the only group to significantly enhance expression of any marker in response to stimulation 
with H1N1 antigen.  While the MLV+Ad5mutIL-18 vaccination group exhibited strong 
responses to heterosubtypic viral antigen post challenge, surprisingly the response to H1N1 
induced strong up-regulation of IL-10, a phenotypic TH2 cytokine.  IL-10 is largely 
recognized for its functions as an anti-inflammatory cytokine that inhibits IFN- expression 
and acts as a negative regulator to TH1 T cell immune responses in murine and human 
models (Couper et al., 2008; Ejrnaes et al., 2006).  However, during the course of influenza 
infection antigen specific effector T cells are known to express high levels of IL-10 (Sun and 
Metzger, 2008).  It has been shown the inhibition of IL-10 signaling during influenza 
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infection results in enhanced damage to the lung (Sun and Metzger, 2008).  Moreover, it has 
been shown in NK cells that IL-10 can act to enhance IFN-production and cytotoxicity of 
NK cells when co-administered with IL-18 (Cai et al., 1999).  Therefore, the up-regulation of 
IL-10 in response to stimulation by heterosubtypic antigen may be the result of a protective 
immune function resulting from influenza infection.  Further study to evaluate the correlation 
between macroscopic lung scores and the level of IL-10 protein in the lungs may prove to 
yield some insight into the possible mechanisms of enhanced damage to the lung resulting 
from heterosubtypic influenza challenge.   
Results show co-administration of mutIL-18 expressing adenoviral vector with an 
attenuated swine influenza MLV vaccine resulted in superior protection to heterosubtypic 
infection as measured by viral shedding, viral replication in the lung, HI titers post 
vaccination and post challenge, macroscopic lung lesions, and by flow cytometric analysis.  
MLV+Ad5mutIL-18 was the only vaccination group to significantly respond to stimulation 
by heterosubtypic viral antigen (Fig. 3.19).  Conversely, the MLV+mutIL-18 vaccination 
group was the highest inducer of CD25 and IFN- expression in response to stimulation by 
homologous viral antigen post challenge, but did not respond in kind to stimulation with 
heterosubtypic antigen (Fig. 3.21, 3.18).  Further research to evaluate the effect of the 
expression vectors on the immune response would be interesting.  The induction of IL-10 in 
response to heterosubtypic viral antigen at one week post challenge was only noted by the 
adenoviral vaccination groups MLV+Ad5mutIL-18 [CD4+, CD4CD8+, CD8+, ] and 
MLV+Ad5wtIL-18 [CD4+, CD4CD8+].   
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CHAPTER 4 GENERAL SUMMARY 
Discussion 
Recombinant porcine IL-18 expression vectors were generated to evaluate the 
immunomodulatory effect of IL-18 on the immune response to an attenuated swine influenza 
MLV vaccine.  Both wtIL-18 and mutIL-18 expression vectors were confirmed to express 
0.1-10 ng/mL rIL-18 protein depending on the conditions tested and the expression vector.  
Expression of rIL-18 by adenoviral vectors resulted in 5-10 fold greater quantities of rIL-18 
protein than the influenza mutIL-18 isolate under similar culturing conditions in vitro.   
Biological activity of wtIL-18 and mutIL-18 was not definitively confirmed.  Initial 
trials utilizing low concentrations of rIL-18 protein and no co-stimulatory agents failed to 
induce any IFN- expression.  Co-stimulating PMBCs with Con A and/or rpIL-12 resulted in 
detectable levels of IFN- production by treatment groups.  However, the unexpected activity 
of negative controls and the apparent variability in responsiveness to treatment between pigs 
complicated the determination of the true biological activity between treatment groups.   
The biological activity trials have indicated the response to treatment groups between 
pigs displays a high degree of variability.  A genetic component, health status, or unidentified 
environmental factor may play a significant role in response to treatment in the in vitro 
biological activity assay.  Additional trials are needed to determine definitively the biological 
activity of the rIL-18 isolates.  The establishment of protocols to generate rIL-18 samples of 
higher concentration would presumably aid in the testing of biological activity.  Repeated 
measures from the same PBMC samples may be needed to account for inherent variability 
between PBMCs from different subjects.  The removal of viral or cellular products while 
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maintaining a high concentration of rIL-18 protein would help ensure accurate measurements 
of biological activity by rIL-18 proteins.   
While the removal of viral and cellular components was attempted by filtration prior 
to protein concentration, compounds between 10kD and 100kD MW remained and were 
concentrated 10-fold.  Furthermore, adenoviral titers in the concentrated adenoviral 
preparations samples were between 1.0 X 10
9
 to 5.6 X 10
9
 TCID50/mL after filtration and 
concentration.  Adenoviruses are able to infect lymphocytes and monocytes (Segerman et al., 
2006; van der Veen and Lambriex, 1973).  Even though adenoviral isolates are replication 
defective, infection alone may cause up-regulation of some immunological pathways.  The 
adenovirus control group Ad5B was able to illicit some level of IFN- protein expression 
when PBMCs were co-stimulated with rpIL-12 or con A/rpIL-12.  The induction of IFN- 
expression by Ad5B is consistent with a previous study (Hartman et al., 2007).  It was 
reported a similar LacZ expressing adenovirus was able to up-regulate Jak/STAT, MAPK, 
TLR, and apoptotic-related pathways as well as induce a MyD88 mediated IFN- response in 
vivo (Hartman et al., 2007).  Adenoviruses are well suited for mucosal administration, 
including oral and intranasal routes, able to elicit high IgA antibody titers and effective 
CD8+ T cell responses (Croyle et al., 2008; Phillpotts et al., 2005; Tang et al., 2009; Tucker 
et al., 2008; Walter et al., 2001; Xiang and Ertl, 1999).  Intranasal administration of rIL-18 
expressing adenoviruses did result in consistent, albeit low, IFN- induced expression in 
nasal wash samples following a time dependent pattern.  Previous studies expressing IFN-
or IL-18 by similar adenoviral vectors in vivo also reported steep declines in expressed 
protein levels on or before day 3 post vaccination (Brockmeier et al., 2009; Walter et al., 
2001).   
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IL-18 expression vectors were administered as part of a single dose swine influenza 
MLV vaccination.  Previous research had shown the swine influenza MLV vaccine 
(Tx98NS1126) was able to elicit protective immunity to homologous and homosubtypic 
challenge but failed to protect against heterosubtypic infection (Richt et al., 2006; Vincent et 
al., 2007).  Results indicate co-administration of mutIL-18 expressing adenoviral vectors 
with the attenuated swine influenza MLV vaccine resulted in superior protection to 
heterosubtypic infection.  MLV+Ad5mutIL-18 vaccination exhibited the strongest protective 
immunological responses to heterosubtypic challenge as measured by viral shedding, viral 
replication in the lung, HI titers post vaccination and post challenge, macroscopic lung 
lesions, and by flow cytometric analysis.  The MLV+Ad5mutIL-18 was the only vaccination 
group to significantly respond to stimulation by heterosubtypic viral antigen (Fig. 3.19).  
Conversely, the MLV+mutIL-18 vaccination group was the highest inducer of CD25 and 
IFN- expression in response to stimulation by homologous viral antigen, but did not respond 
in kind to stimulation with heterosubtypic antigen (Figure 3.21, 3.18).  Further research to 
evaluate the effect of the expression vectors on the immune response would be interesting.  
The induction of IL-10 in response to heterosubtypic viral antigen at one week post challenge 
was only noted by the adenoviral vaccination groups MLV+Ad5mutIL-18 [CD4+, 
CD4CD8+, CD8+, ] and MLV+Ad5wtIL-18 [CD4+, CD4CD8+].  This may be a product 
of the enhance level of rIL-18 expression, or it may be due to the adenovirus itself.  It would 
be interesting to evaluate the protein concentration of IL-10 and IFN-in BALF samples and 
see if IL-10 protein concentrations correlate directly to reduced pneumonic lung lesions in 
response to heterosubtypic immunity.  If a direct correlation is found, it may indicate a 
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possible mechanism for the enhanced pneumonic lung lesions in response to heterosubtypic 
challenge.   
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APPENDIX A  WTIL-18 AND MUTIL-18 SEQUENCE ANALYSIS 
Appendix A.1 wtIL-18/ mutIL-18 cDNA sequence alignment 
Figure A.1  Sequence alignment of wtIL-18 and mutIL-18 cDNA constructs 
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Appendix A.2 wtIL-18/mutIL-18 amino acid alignment 
Figure A.2  wtIL-18/mutIL-18 amino acid alignment  
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Appendix A.3 Sequence assessment of adenoviral gene insertions 
 
Figure A.3  Sequence assessment of adenoviral gene insertions 
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Appendix A.4 Chemical structure comparison of human versus porcine mutIL-
18 amino acid conversions 
 Kim et al. (2001, 2002) identified two amino acids by computer modeling as 
important residues for the binding of IL-18 to IL-18BP.  Mutations to these sites inverting the 
charged residues (E42K or K89E) resulted in mixed results.  While the K89E mutation 
resulted in a 95% reduction in biological activity, the E42K resulted in 2-fold biological 
activity (Kim et al, 2002).  Converting E42 and K89 to alanine (E42A and K89A) resulted in 
a 4-fold increase in biological activity and rendered fully resistant to neutralization by IL-
18BP.  To evaluate if synonymous mutations would result in enhanced biological activity, a 
mutated IL-18 was generated by PCR primer site directed mutagenesis (E41A & K88A) from 
a wild type porcine cDNA.  Human IL-18 contains an valine (V6) at amino acid position 6 
which is not found in the wild type porcine IL-18 cDNA construct. 
Figure A.4  Chemical structure comparison of human versus porcine mutIL-18 amino 
acid conversions 
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APPINDIX B  ADDITIONAL MATERIALS 
AppendixB.1 Evaluation of IFN- production at various Con A concentrations 
To evaluate the effect of Con A concentration on IFN- production by porcine 
PBMCs, titration of Con A concentratons were performed on PMBCs from three sows (age 
unknown, NADC animal services) (Fig. 2.6).  Approximately 5.5 X 10
5
 PBMCs per cm
2
 
were plated in 0.5mL supplimented RPMI 1640 stimulated with 0.0-2.5 μg/mL Con A (final 
concentration).  Samples were collected after a 24 hour incubation period and IFN- levels 
measured in duplicate by swine IFN- ELISA.  Con A induced expression of IFN- was 
found to platue as increasing concentations of ConA past 1.0-2.0 μg/mL.   
 
Figure B.1  Determination of sub-optimal concentrations of Concanavalin A 
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 Fig. A 2.5.  IFN- production analysis of PBMCs stimulated with increasing concentrations of Con A.  PBMCs stimulated 
with various concentrations of Con A were incubated at 39oC/ 5% CO2 for 24 hours.  PBMC supernatants were measured in 
duplicate by swine IFN- ELISA.  Values are the result of a single trial of 3 pigs. 
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Table B.1  Evaluation of IFN- production at various Con A concentrations 
Trial: ConA Dilutions Start Date 11.21.08
ELISA Date 11.24.08
Time Point:  24hr
Volume:  Final volume equals 0.5mL per well
Plate  48-well flat bottom cell culture plate (COSTAR) 
PBMC/well:  4.17 x 10^5
Set-up:  Percoll extracted PBMC's treated with varying concentrations of 
 ConA (from 0.0mg/mL to 2.5mg/mL); steps of 0.5mg/mL
Media:  RPMI 1X suplimented with FBS [5% final concentration] 
(Alanta Biologicals) 1X Antibiotic/Antimycotic (GIBCO)
ConA Stock:  5mg/mL Stock aliquat, F/T 1X.  Reconstituted lyophilized ConA (SIGMA) 
Final Conc. Media ConA Stock Total Count / mL Vol / well PBMC/well
Dilutions: 2.5mg/mL ConA250μL 250μL Pig 1 21.14 x 10^6 197μL 4.16 x 10^5
2.0mg/mL ConA300μL 200μL Pig 2 17.1 x 10^6 24.4μL 4.17 x 10^5
1.5mg/mL ConA350μL 150μL Pig 3 22.2 x 10^6 18.8μL 4.17 x 10^5
1.0mg/mL ConA400μL 100μL 
0.5mg/mL ConA450μL 50μL 
0.0mg/mL ConA500μL 0μL 
PBMC Isolation from whole blood (Animal Services, NADC) from 3 donar swine was preformed
via the percoll PBMC protocol [previous work, Dr. Kehrli].  Isolated PBMCs were
 resuspended into 1mL media (as described above) and CBCs were preformed using the 
Hemavet hemacytomoter.  Dilutions were preformed to obtain a cell count of 4.17 x 10^5 
PBMC/well.  Desired cell counts were calculated baised on previous work (Dr. Kehrli) 
using a 96-well format [200,000 PBMC/well].  Corrections for surface area differences 
were made.  Each set of concentrations were set up in duplicate [per pig] so that different 
assays could be ran (1F/T to 3F/T).  See furthere explination below.
Duplicates F/T 3X:  Samples frozen while in the plate 3X, upon the third thaw IFNg levels 
measured via a swine Interferon-g ELISA (INVITROGEN); 
F/T 0X:  Repeated aspiration of media within individual wells will resuspend PBMCs.  
Resuspended PBMCs+Media will be moved to individually labeled steril 1.5mL tubes to 
be spun at 1500 RPM [200RCF] for 10 minutes to pellet PBMC's.  Resulting media was 
aspirated off and stored within individual tubes, to be assessed for IFNg levels via a swine 
Interferon-g ELISA (INVITROGEN) and than properly stored at -80C.  Pelleted PBMCs 
were individually lysed and total RNA extracted via the Total RNA MagMax extraction kit.  
Extracted RNA may be assessed via a IFNg qPCR assay for transcriptional levels of 
IFNg mRNA
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Appendix B.2 Concentrated rIL-18 biological activity assay: IFN- (pg/mL) per 
time point by pig  
Table B.2  Concentrated IL-18 biological activity data per pig:  
Biological Activity Assay:  IFN(pg/mL)
Treatment groups: Concentrated adenoviral preparations 
Co-stimulation:  rpIL-12 (100ng/mL)
Treatment Group Timepoint Pig 1 Pig 2 Pig 3 Pig 4
Ad5B 24 h 32.87 0.00 0.00 0.00
Ad5B 48 h 347.70 1.59 0.00 2.53
Ad5B 72 h 1160.32 73.12 5.07 0.00
Ad5B 96 h 1174.03 185.33 45.93 0.00
Ad5B 120 h 1145.02 351.64 264.86 0.00
Ad5+wtIL-18K:E 24 h 25.98 0.00 0.00 0.25
Ad5+wtIL-18K:E 48 h 276.27 12.68 7.63 4.49
Ad5+wtIL-18K:E 72 h 384.77 34.52 16.13 9.52
Ad5+wtIL-18K:E 96 h 513.66 21.58 8.68 4.36
Ad5+wtIL-18K:E 120 h 500.19 79.63 85.80 7.42
Ad5+mutIL-18K:F2 24 h 49.37 0.00 0.00 0.00
Ad5+mutIL-18K:F2 48 h 891.29 5.52 11.59 0.09
Ad5+mutIL-18K:F2 72 h 1639.77 16.71 6.69 0.00
Ad5+mutIL-18K:F2 96 h 3034.33 88.92 2.03 19.55
Ad5+mutIL-18K:F2 120 h 2404.15 248.19 5.57 7.55
Ad5+mutIL-18K:E3 24 h 114.99 0.00 0.00 0.00
Ad5+mutIL-18K:E3 48 h 1725.82 13.55 23.55 0.00
Ad5+mutIL-18K:E3 72 h 3098.56 67.13 297.75 20.58
Ad5+mutIL-18K:E3 96 h 3401.10 243.08 107.34 11.77
Ad5+mutIL-18K:E3 120 h 6650.70 630.59 151.23 5.67
IFN(pg/mL)
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Appendix B.3 Interleukin-18/MLV vaccination evaluation in response to 
heterosubtypic challenge: animal study experimental outline 
Experimental Outline 
Effect of Interleukin-18 on Vaccination Efficacy of Influenza Tx98NS1Δ126 MLV  
ACUC Protocol 3846    IBC Protocol  0273, 0310, 0311 
Table B.3  IL-18/influenza MLV vaccination animal study: group outline 
Group N Description ID Challenge
1 8   Adeno 5 w/ mSwIL-18 Insertion Ad5mutIL-18 IA04
2 8   Tx98NS1Δ126 + Adeno 5 w/ wtSwIL-18 Insertion MLV+Ad5wtIL-18 IA04
3 8   Tx98NS1Δ126 + Adeno 5 w/ mSwIL-18 insertion MLV+Ad5mutIL-18 IA04
4 8   Tx98NS1Δ126 w/ mSwIL-18 insertion MLV+mIL-18 IA04
5 8   Tx98NS1Δ126 MLV IA04
6 8   Wild type Tx98 wtTx98 IA04
Vaccine Treatment Group
 
11/13/08 60 pigs delivered to NADC - 48 pigs to Barn 3A.  8 per room, 4 per crate X 2.  Administer 
EXCEDE per label dose and tag. 
11/20/08 Collect serum to confirm seronegativity to influenza virus and a nasal swab sample per pig.  
Intranasal administration of 2 mL inoculum to respective groups 
11/22/08  Nasal swab and bleed 
11/24/08  Nasal swab and bleed 
11/26/08  Nasal swab and bleed 
12/4/08    Bleed for serum 
12/11/08  Bleed for serum 
12/18/08  Bleed for serum and PBMC harvest 
1/8/09      Bleed for serum and PBMC harvest 
1/15/09    Bleed for serum and PBMC harvest 
1/22/09    Rectal temperature.   
1/23/09    Rectal temperature.   
1/24/09    Challenge (all groups) with IA04 wild-type strain (A/swine/Iowa/00239/2004).  Pre-
challenge: nasal swab, rectal temperature, and serum collection.   
1/25/09    Rectal temperature.  Observe for clinical manifestation of infection. 
1/26/09    Rectal temperature.  Observe for clinical manifestation of infection. 
1/27/09    Nasal swab and rectal temperature.  Observe for clinical manifestation of infection. 
1/28/09    Rectal temperature.  Observe for clinical manifestation of infection. 
1/29/09    Serum Collection, nasal swab, PBMC collection, and rectal temperature.  Observe for 
clinical manifestation of infection.  Necropsy. 
 
Primary Inoculum:  
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Influenza: A dose of 2 mL ~1.0 X 10
6.5 
TCID50/mL of egg derived wtTx98 H3N2 
(A/Swine/Texas/4199-2/98), Tx98NS1Δ126 (A/Swine/Texas/4199-2/98), or Tx98 
NS1Δ126+mutIL-18 insertion (A/Swine/Texas/4199-2/98) were administered intranasally 
to the respective groups.   
 
Adenovirus:  A dose of 2 mL ~1.0 X10
9
 TCID50/mL of CsCl concentrated/purified 
Ad5+wtSwIL-18 insertion or Ad5+mSwIL-18 insertion were administered to 
respective groups intranasally.   
 
Challenge:   
Influenza: A dose of 2 mL ~1.0 X 10
6.83
 TCID50/mL (A/swine/Iowa/00239/2004) virus 
administered intranasally to all treatment groups. 
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APPENDIX C FLOW CYTOMETRY DATA ANALYSIS: CELL 
MEDIATED IMMUNITY ASSAY 
Figure C.1  CMI Assay: CD25 EI by group 4 weeks post vaccination 
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Figure C.2  CMI Assay: CD25 EI by antigen 4 weeks post vaccination 
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Figure C.3  CMI Assay: IFN- EI by group 4 weeks post vaccination 
 
 143 
 
Figure C.4  CMI Assay: IFN- EI by antigen 4 weeks post vaccination 
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Figure C.5  CMI Assay: IL-10 EI by group 4 weeks post vaccination 
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Figure C.6  CMI Assay: IL-10 EI by antigen 4 weeks post vaccination 
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Figure C.7  CMI Assay: CD25 EI by group 7/8 weeks post vaccination 
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Figure C.8  CMI Assay: CD25 EI by antigen 7/8 weeks post vaccination 
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Figure C.9  CMI Assay: IFN- EI by group 7/8 weeks post vaccination 
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Figure C.10  CMI Assay: IFN- EI by antigen 7/8 weeks post vaccination 
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Figure C.11  CMI Assay: IL-10 EI by group 7/8 weeks post vaccination 
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Figure C.12  CMI Assay: IL-10 EI by antigen 7/8 weeks post vaccination 
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Figure C.13  CMI Assay: CD25 EI by group 10 weeks post vaccination 
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Figure C.14  CMI Assay: CD25 EI by antigen 10 weeks post vaccination 
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Figure C.15  CMI Assay: IFN- EI by group 10 weeks post vaccination 
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Figure C.16  CMI Assay: IFN- EI by antigen 10 weeks post vaccination 
 
 156 
 
Figure C.17  CMI Assay: IL-10 EI by group 10 weeks post vaccination 
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Figure C.18  CMI Assay: IL-10 EI by antigen 10 weeks post vaccination 
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